Updated on 2023/09/29

写真a

 
HORI Mika
 
Organization
Research Institute of Environmental Medicine Division of Stress Adaptation and Protection Lecturer
Graduate School
Graduate School of Medicine
Title
Lecturer
External link

Degree 1

  1. 博士(薬学) ( 2008.3   北海道大学 ) 

Research Areas 2

  1. Life Science / Pathological biochemistry

  2. Life Science / Metabolism and endocrinology

Research History 2

  1. 名古屋大学 環境医学研究所   内分泌代謝分野   講師

    2020.7

  2. National Cerebral and Cardiovascular Center, Research Institute

    2020.7

Professional Memberships 6

  1. 日本動脈硬化学会

  2. 日本癌学会

  3. 日本循環器学会

  4. 日本分子生物学会

  5. 日本がん予防学会

  6. 日本心血管内分泌学会

▼display all

Committee Memberships 5

  1. 日本動脈硬化学会   ダイバーシティ委員  

    2022.10   

  2. 日本動脈硬化学会   メディカルスタッフ賞選考委員  

    2022.10   

  3. 日本がん予防学会   評議員  

    2021.9   

      More details

    Committee type:Academic society

  4. 日本動脈硬化学会   評議員  

    2018.7   

      More details

    Committee type:Academic society

  5. 日本動脈硬化学会   男女共同参画委員  

    2016.7 - 2020.6   

      More details

    Committee type:Academic society

Awards 7

  1. 第20回大学女性協会守田科学研究奨励賞

    2018.6  

  2. 2016年度動脈硬化 update 優秀賞

    2016.9  

    堀 美香

  3. 第47回日本動脈硬化学会総会・学術集会優秀ポスター賞

    2015.7  

    堀 美香

  4. 国立循環器病研究センター 平成26年度若手研究奨励賞

    2014.12  

    堀 美香

  5. 第18回 (平成22年度) 膵臓病研究財団研究奨励賞

    2010.12  

    堀 美香

  6. 平成19年度北海道大学大塚賞

    2008.3  

    堀 美香

  7. The Environmental Mutagen Society Student Travel Award

    2005.9  

    堀 美香

▼display all

 

Papers 62

  1. A Low-Frequency APOB p.(Pro955Ser) Variant Contributes to the Severity of/Variability in Familial Hypercholesterolemia Reviewed

    Hori Mika, Takahashi Atsushi, Hosoda Kiminori, Ogura Masatsune, Harada-Shiba Mariko

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 108 ( 2 ) page: 422 - 432   2023.1

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:The Journal of clinical endocrinology and metabolism  

    CONTEXT: Heterozygous familial hypercholesterolemia (HeFH) is caused by a rare pathogenic variant in the LDLR, APOB, and PCSK9 genes. However, the causative variants in these genes have not been identified in approximately 40% of HeFH patients. OBJECTIVE: Our aim was to identify novel (or additional) genes/variants that contribute to HeFH. METHODS: Whole-exome sequencing was performed for 215 family members from 122 families with HeFH without pathogenic variants in the LDLR or PCSK9 genes. RESULTS: We could not find novel causative familial hypercholesterolemia (FH) genes/variants by family analysis. Next, we examined all APOB variants. Twenty-four nonsynonymous APOB variants were identified. The allele frequencies of the c.2863C > T:p.(Pro955Ser) variant in the HeFH probands and the general Japanese population were 0.15 and 0.034, respectively [odds ratio 4.9 (95% CI 3.4-7.1); P = 6.9 × 10-13]. The patients harboring the c.2863C > T:p.(Pro955Ser) variant accounted for 9.8% (n = 63) of unrelated patients with HeFH (n = 645). The penetrance of the c.2863C > T:p.(Pro955Ser) variant was low in the pedigree-based genetic analysis. In an in vitro assay, low-density lipoprotein (LDL) uptake from patients with the homozygous c.2863C > T:p.(Pro955Ser) variant was 44% of the LDL uptake from control subjects, and it was similar to that of the LDL uptake from patients with the known pathogenic heterozygous p.(Arg3527Gln) variant. CONCLUSIONS: The low-frequency APOB c.2863C > T:p.(Pro955Ser) variant is not an FH-causative variant, but it has a moderate effect size in HeFH. These findings suggest that the combination of the APOB c.2863C > T:p.(Pro955Ser) variant and age, environmental factors, or other genetic factors contributes to the severity of or variability in the HeFH phenotype.

    DOI: 10.1210/clinem/dgac572

    Web of Science

    Scopus

    PubMed

  2. The impact of gene variants on the thickness and softness of the Achilles tendon in familial hypercholesterolemia. Reviewed

    Michikura M, Hori M, Ogura M, Hosoda K, Harada-Shiba M

    Atherosclerosis   Vol. 358   page: 41 - 46   2022.10

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Atherosclerosis  

    Background and aims: Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein (LDL)-cholesterol, xanthoma of the Achilles tendon (AT), and premature coronary artery disease (CAD). Ultrasonography can assess AT thickness and softness, making it useful for evaluating AT in FH diagnosis. We aimed to clarify whether FH-causative LDLR or PCSK9 variants affect AT thickness or softness. Methods: In total, 248 FH and 60 non-familial hypercholesterolemia (non-FH) patients (total: 308) aged ≥30 years were enrolled. Patients with FH were classified according to genotype. AT thickness and elasticity index (EI) as softness were measured by ultrasonography. Results: In FH patients with LDLR variants, AT was significantly thicker and softer than it was in FH patients with PCSK9 variants, FH patients without LDLR or PCSK9 variants, and patients with non-FH. The proportion of patients harboring LDLR variants significantly increased with AT thickness (p = 2.0 × 10−31) and softness (p = 1.4 × 10−18). Among those with AT thickness>8.5 mm and EI < 3.9, patients with LDLR variants accounted for 89% and 83%, respectively. The odds of AT thickening, AT softening and CAD increased 13.3-fold, 4.9-fold, and 2.1-fold, adjusted for the LDL-C year score by the presence of LDLR variants compared with those of patients without LDLR or PCSK9 variants. PCSK9 variants did not influence AT thickening or softening or CAD prevalence. Conclusions: LDLR variants affected AT thickness and softness independent of the LDL-C year score, but PCSK9 variants did not. Evaluating AT is important for identifying FH patients with LDLR variants at high risk for CAD.

    DOI: 10.1016/j.atherosclerosis.2022.08.014

    Scopus

    PubMed

  3. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. Reviewed

    Hori M, Ohta N, Takahashi A, Masuda H, Isoda R, Yamamoto S, Son C, Ogura M, Hosoda K, Miyamoto Y, Harada-Shiba M

    Atherosclerosis   Vol. 289   page: 101-108   2019.10

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.atherosclerosis.2019.08.004

    PubMed

  4. Humoral factors secreted from adipose tissue-derived mesenchymal stem cells ameliorate atherosclerosis in Ldlr-/- mice. Reviewed

    Takafuji Y, Hori M, Mizuno T, Harada-Shiba M

    Cardiovascular research   Vol. 115 ( 6 ) page: 1041-1051   2019.5

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/cvr/cvy271

    PubMed

  5. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. Reviewed

    Ohta N, Hori M, Takahashi A, Ogura M, Makino H, Tamanaha T, Fujiyama H, Miyamoto Y, Harada-Shiba M

    Journal of clinical lipidology   Vol. 10 ( 3 ) page: 547 - 555.e5   2016.5

     More details

    Authorship:Lead author, Corresponding author  

    DOI: 10.1016/j.jacl.2015.12.024

    PubMed

  6. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. Reviewed

    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M

    The Journal of clinical endocrinology and metabolism   Vol. 100 ( 1 ) page: E41 - 9   2015.1

     More details

    Authorship:Lead author  

    DOI: 10.1210/jc.2014-3066

    PubMed

  7. Amplified Risk of Intracranial Artery Stenosis/Occlusion Associated With RNF213 p.R4810K in Familial Hypercholesterolemia. Reviewed

    Noda K, Hattori Y, Hori M, Nakaoku Y, Tanaka A, Yoshimoto T, Nishimura K, Yokota T, Harada-Shiba M, Ihara M

    JACC. Asia   Vol. 3 ( 4 ) page: 625 - 633   2023.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JACC: Asia  

    Background: The RNF213 p.R4810K variant is associated with moyamoya disease in East Asian individuals and increases the risk of developing intracranial major artery stenosis/occlusion (ICASO) that affects anterior circulation. Meanwhile, 0.5% to 2.5% of asymptomatic East Asian individuals also carry this variant. As such, additional factors are likely required to develop ICASO in variant carriers. Familial hypercholesterolemia (FH) is a common genetic disorder in Japan that has a significant associated risk of developing premature coronary atherosclerosis; however, the relationship between ICASO and FH remains unknown. Objectives: This study aimed to determine if FH facilitates RNF213 p.R4810K carriers to develop ICASO. Methods: We enrolled patients with FH who had undergone brain magnetic resonance angiography at our hospital from May 2005 to March 2020. The RNF213 p.R4810K variant, and LDLR and PCSK9 mutations were genotyped. ICASO lesions in the brain magnetic resonance angiogram were analyzed. Results: Six RNF213 p.R4810K variant carriers were identified among 167 patients with FH (LDLR, n = 104; PCSK9, n = 22). Five of the carriers (83.3%) exhibited ICASO in the anterior circulation; a significant difference in ICASO frequency was observed between the variant carriers and noncarriers (P = 0.025). The median number of stenotic or occluded arteries in the anterior circulation was also significantly larger in the variant carriers (3 vs 1, P = 0.01); however, did not differ between patients with FH with LDLR and PCSK9 mutations. Conclusions: Patients with FH exhibit increased prevalence and severity of ICASO associated with RNF213 p.R4810K. Gene mutations for FH may confer an increased risk of ICASO in RNF213 p.R4810K carriers.

    DOI: 10.1016/j.jacasi.2023.03.011

    Scopus

    PubMed

  8. Association between Familial Hypercholesterolemia and Serum Levels of Cholesterol Synthesis and Absorption Markers: The CACHE Study FH Analysis. Reviewed

    Kota Matsuki, Mariko Harada-Shiba, Mika Hori, Masatsune Ogura, Yusuke Akiyama, Hisako Fujii, Yutaka Ishibashi, Tatsuro Ishida, Yasushi Ishigaki, Daijiro Kabata, Yasuki Kihara, Kazuhiko Kotani, Satoshi Kurisu, Daisaku Masuda, Tetsuya Matoba, Takeshi Matsumura, Kenta Mori, Tomoko Nakagami, Masamitsu Nakazato, Satsuki Taniuchi, Hiroaki Ueno, Shizuya Yamashita, Hiroshi Yoshida, Hisako Yoshida, Tetsuo Shoji

    Journal of atherosclerosis and thrombosis   Vol. advpub ( 0 )   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japan Atherosclerosis Society  

    AIM: Serum levels of cholesterol absorption and synthesis markers are known to be associated with cardiovascular risk. Familial hypercholesterolemia (FH) is a well-known inherited disorder presenting elevated low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) levels and premature coronary disease. In this study, we aim to examine the differences in terms of serum markers of cholesterol metabolism between FH and non-FH individuals and to examine their associations with serum lipid levels. METHODS: In this study, we utilized data on serum markers of cholesterol metabolism, namely, lathosterol (Latho, synthesis marker), campesterol (Campe, absorption marker), and sitosterol (Sito, absorption marker) measured by gas chromatography of the CACHE consortium, which comprised of 13 research groups in Japan. Clinical data were compiled using REDCap system. Among the 2944 individuals in the CACHE population, we selected individuals without lipid-lowering medications and hemodialysis patients for this CACHE study FH analysis. Multivariable adjustment was performed to assess the associations. RESULTS: In this study, we analyzed data from 51 FH patients and 1924 non-FH individuals. After adjustment for possible confounders, the FH group was shown to have significantly higher Campe and Sito concentrations and insignificantly higher Latho concentrations than the non-FH group. These marker concentrations showed nonlinear associations with TC in the FH group. Campe/Latho and Sito/Latho ratios were significantly higher in the FH group than in the non-FH group. CONCLUSION: FH group had significantly elevated serum Campe and Sito concentrations and insignificantly elevated Latho concentrations; thus, intestinal cholesterol absorption relative to hepatic cholesterol synthesis was suggested to be elevated in patients with FH. Serum Latho, Campe, and Sito concentrations showed nonlinear associations with TC in the FH group.

    DOI: 10.5551/jat.63899

    PubMed

    CiNii Research

  9. Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels. International journal

    Sayaka Funabashi, Yu Kataoka, Mika Hori, Masatsune Ogura, Takahito Doi, Teruo Noguchi, Mariko Harada-Shiba

    Journal of the American Heart Association   Vol. 11 ( 16 ) page: e025232   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background Heterozygous familial hypercholesterolemia (HeFH) more likely exhibits extensive atherosclerotic disease at multiple vascular beds. Lipoprotein(a) (Lp(a)) is an atherogenic lipoprotein that elevates HeFH-related atherosclerotic cardiovascular disease risks. Whether circulating Lp(a) level associates with polyvascular propagation of atherosclerosis in subjects with HeFH remains uncertain. Methods and Results The current study analyzed 370 subjects with clinically diagnosed HeFH who received evaluation of systemic arteries. Polyvascular disease (polyVD) was defined as more than 2 coexisting atherosclerosis conditions including coronary artery disease, carotid stenosis, or peripheral artery disease. Clinical characteristics and lipid features were analyzed in subjects with HeFH and polyVD; 5.7% of patients with HeFH (21/370) had polyVD. They were more likely to have a clustering of risk factors, tendon (P<0.001) and skin xanthomas (P=0.004), and corneal arcus (P=0.026). Furthermore, an elevated Lp(a) level (P=0.006) and a greater frequency of Lp(a) level ≥50 mg/dL (P<0.001) were observed in subjects with HeFH and polyVD. On multivariable analysis adjusting risk factors and lipid-lowering agents, Lp(a) ≥50 mg/dL (odds ratio [OR], 5.66 [95% CI, 1.68-19.0], P=0.005), age, and family history of premature coronary artery disease independently predicted polyVD in subjects with HeFH. Of note, the prevalence of polyVD rose to 33.3% in patients with HeFH and age >58 years old, family history of premature coronary artery disease, and Lp(a) ≥50 mg/dL (OR, 10.3 [95% CI, 3.12-33.4], P<0.001). Conclusions An increased level of circulating Lp(a) levels predicted concomitance of polyVD in patients with HeFH. The current findings suggest subjects with HeFH and Lp(a) ≥50 mg/dL as a high-risk category who require meticulous screening of systemic vascular beds.

    DOI: 10.1161/JAHA.121.025232

    Web of Science

    Scopus

    PubMed

  10. Acute Cholesterol-Lowering Effect of Exendin-4 in Ldlr-/- and C57BL/6J Mice. Reviewed

    Mika Hori, Yukiko Hasegawa, Yoshitaka Hayashi, Tomoko Nakagami, Mariko Harada-Shiba

    Journal of atherosclerosis and thrombosis   Vol. advpub ( 0 )   2022.3

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japan Atherosclerosis Society  

    AIMS: We previously reported that glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduced serum low-density lipoprotein cholesterol (LDL-C) levels in patients with type 2 diabetes mellitus receiving statins, which increased LDL receptor (LDLR) expression. Nevertheless, it remains unclear how much LDLR expression contributes to the LDL-C-lowering effect of GLP-1RAs. We examined the effect of a GLP-1RA, namely, exendin-4, on serum LDL-C levels and its mechanism in Ldlr-/- and C57BL/6J mice. METHODS: Ten-week-old Ldlr-/- and C57BL/6J mice received exendin-4 or saline for 5 days, and serum lipid profiles and hepatic lipid levels were examined. Cholesterol metabolism-related gene expression and protein levels in the liver and ileum and the fecal bile acid (BA) composition were also examined. RESULTS: Exendin-4 treatment significantly decreased serum very-low-density lipoprotein cholesterol (VLDL-C) and LDL-C levels and mature hepatic SREBP2 levels and increased hepatic Insig1/2 mRNA expression in both mouse strains. In Ldlr-/- mice, exendin-4 treatment also significantly decreased hepatic cholesterol levels and fecal BA excretion, decreased hepatic Cyp7a1 mRNA expression, and increased small intestinal Fgf15 mRNA expression. In C57BL/6J mice, exendin-4 treatment significantly decreased small intestinal NPC1L1 levels. CONCLUSIONS: Our findings demonstrate that exendin-4 treatment decreased serum VLDL-C and LDL-C levels in a manner that was independent of LDLR. Exendin-4 treatment might decrease serum cholesterol levels by lowering hepatic SREBP2 levels and cholesterol absorption in Ldlr-/- and C57BL/6J mice. Exendin-4 treatment might decrease cholesterol absorption by different mechanisms in Ldlr-/- and C57BL/6J mice.

    DOI: 10.5551/jat.60921

    PubMed

  11. Identification of a novel large duplication (exon2_6dup): copy number variation in the LDLR gene in a large family with familial hypercholesterolemia by whole-genome sequencing. Reviewed International journal

    Mika Hori, Atsushi Takahashi, Kiminori Hosoda, Mariko Harada-Shiba

    Journal of clinical lipidology   Vol. 16 ( 2 ) page: 167 - 172   2022.3

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: We found a large family with familial hypercholesterolemia (FH) that included 7 siblings who all developed myocardial infarction. OBJECTIVE: The aim of this study was to identify the pathogenic gene underlying FH in the family. METHODS: Whole-genome sequencing (WGS) was performed in 12 affected and 10 unaffected individuals in the family. RESULTS: WGS identified a novel large duplication: copy number variation (CNV) in the LDLR gene, exon2_6dup (c.68-499_940+252dup), that was present in the 12 affected family members but not in any of the 10 unaffected family members. The exact extent and genomic breakpoint sequence of the duplication caused by nonallelic homologous recombination between Alu sequences were identified based on bioinformatic analysis of WGS data for the LDLR gene. CONCLUSIONS: A novel c.68-499_940+252dup variant in the LDLR gene was identified based on bioinformatic analysis of WGS data. WGS is a powerful tool that can be used to precisely identify CNVs in addition to small-scale variations in FH-related genes.

    DOI: 10.1016/j.jacl.2022.01.007

    Scopus

    PubMed

  12. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study Reviewed International coauthorship

    Tromp T.R., Hartgers M.L., Hovingh G.K., Vallejo-Vaz A.J., Ray K.K., Soran H., Freiberger T., Bertolini S., Harada-Shiba M., Blom D.J., Raal F.J., Cuchel M., Tromp T.R., Hovingh G.K., Ray K.K., Bertolini S.A., Pang J., Watts G.F., Greber-Platzer S., Mäser M., Stulnig T.M., Ebenbichler C.F., Bin Thani K., Cassiman D., Descamps O.S., Rymen D., Witters P., Santos R.D., Brunham L.R., Francis G.A., Genest J., Hegele R.A., Kennedy B.A., Ruel I., Sherman M.H., Jiang L., Wang L., Reiner Ž., Blaha V., Ceska R., Dvorakova J., Dlouhy L., Horak P., Soska V., Tichy L., Urbanek R., Vaverkova H., Vrablik M., Zemek S., Zlatohlavek L., Emil S., Naguib T., Reda A., Béliard S., Bruckert E., Gallo A., Elisaf M.S., Kolovou G., Cohen H., Durst R., Dann E.J., Elis A., Hussein O., Leitersdorf E., Schurr D., Setia N., Verma I.C., Alareedh M.D., Al-Khnifsawi M., Abdalsahib Al-Zamili A.F., Rhadi S.H., Shaghee F.K., Arca M., Averna M., Bartuli A., Bucci M., Buonuomo P.S., Calabrò P., Calandra S., Casula M., Catapano A.L., Cefalù A.B., Cicero A.F.G., D'Addato S., D'Erasmo L., Di Costanzo A., Fasano T., Gazzotti M., Giammanco A., Iannuzzo G., Ibba A., Negri E.A., Pasta A., Pavanello C., Pisciotta L., Rabacchi C., Ripoli C., Sampietro T.

    The Lancet   Vol. 399 ( 10326 ) page: 719 - 728   2022.2

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:The Lancet  

    Background: Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder resulting in extremely elevated low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). Current guidance about its management and prognosis stems from small studies, mostly from high-income countries. The objective of this study was to assess the clinical and genetic characteristics, as well as the impact, of current practice on health outcomes of HoFH patients globally. Methods: The HoFH International Clinical Collaborators registry collected data on patients with a clinical, or genetic, or both, diagnosis of HoFH using a retrospective cohort study design. This trial is registered with ClinicalTrials.gov, NCT04815005. Findings: Overall, 751 patients from 38 countries were included, with 565 (75%) reporting biallelic pathogenic variants. The median age of diagnosis was 12·0 years (IQR 5·5–27·0) years. Of the 751 patients, 389 (52%) were female and 362 (48%) were male. Race was reported for 527 patients; 338 (64%) patients were White, 121 (23%) were Asian, and 68 (13%) were Black or mixed race. The major manifestations of ASCVD or aortic stenosis were already present in 65 (9%) of patients at diagnosis of HoFH. Globally, pretreatment LDL cholesterol levels were 14·7 mmol/L (IQR 11·6–18·4). Among patients with detailed therapeutic information, 491 (92%) of 534 received statins, 342 (64%) of 534 received ezetimibe, and 243 (39%) of 621 received lipoprotein apheresis. On-treatment LDL cholesterol levels were lower in high-income countries (3·93 mmol/L, IQR 2·6–5·8) versus non-high-income countries (9·3 mmol/L, 6·7–12·7), with greater use of three or more lipid-lowering therapies (LLT; high-income 66% vs non-high-income 24%) and consequently more patients attaining guideline-recommended LDL cholesterol goals (high-income 21% vs non-high-income 3%). A first major adverse cardiovascular event occurred a decade earlier in non-high-income countries, at a median age of 24·5 years (IQR 17·0–34·5) versus 37·0 years (29·0–49·0) in high-income countries (adjusted hazard ratio 1·64, 95% CI 1·13–2·38). Interpretation: Worldwide, patients with HoFH are diagnosed too late, undertreated, and at high premature ASCVD risk. Greater use of multi-LLT regimens is associated with lower LDL cholesterol levels and better outcomes. Significant global disparities exist in treatment regimens, control of LDL cholesterol levels, and cardiovascular event-free survival, which demands a critical re-evaluation of global health policy to reduce inequalities and improve outcomes for all patients with HoFH. Funding: Amsterdam University Medical Centers, Location Academic Medical Center; Perelman School of Medicine at the University of Pennsylvania; and European Atherosclerosis Society

    DOI: 10.1016/S0140-6736(21)02001-8

    Scopus

  13. Relationship Of RNF213p.R4810k Variant And Familial Hypercholesterolemia To Intracranial Major Arterial Stenosis/occlusion

    Kotaro Noda, Yorito Hattori, Mika Hori, Akito Tanaka, Mariko Harada-Shiba, Masafumi Ihara

    STROKE   Vol. 53   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    DOI: 10.1161/str.53.suppl_1.TMP78

    Web of Science

  14. Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia Reviewed

    Michikura Masahito, Ogura Masatsune, Hori Mika, Matsuki Kota, Makino Hisashi, Hosoda Kiminori, Harada-Shiba Mariko

    Journal of Atherosclerosis and Thrombosis   Vol. advpub ( 0 )   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japan Atherosclerosis Society  

    <p><b>Aims: </b>Achilles tendon (AT) xanthomas are a specific physical finding of familial hypercholesterolemia (FH) and AT thickness has been used for its diagnosis and evaluation of its severity. Recently, we reported that the AT of FH patients was softer than that of non-FH patients and the combined use of a cut-off value for AT softness with that for AT thickness improved diagnostic accuracy. However, an association between AT softness and severity of atherosclerosis has not been reported. Accordingly, the present study aimed to investigate whether AT softness was associated with carotid atherosclerosis and presence of atherosclerotic cardiovascular disease (ASCVD) in FH.<b> </b></p><p><b>Methods: </b>The AT of 176 genetically diagnosed FH patients and 98 non-FH patients was examined to measure AT thickness and the elasticity index (EI) as an indicator for assessing AT softness using ultrasonography.<b> </b></p><p><b>Results: </b>Increased age was associated with AT softness, and overweight was negatively related to AT softness. There were significant inverse correlations between EI and maximum and mean intima-media thickness (IMT) within the common carotid artery only among FH patients. In multiple linear regression analysis, although the relationship between EI and mean IMT was attenuated, the association between EI and maximum IMT remained robust. In logistic regression analysis adjusted for age, sex and traditional cardiovascular risk factors (smoking history, presence of hypertension, presence of diabetes mellitus, overweight, LDL-cholesterol, HDL-cholesterol, and Log triglycerides), EI was associated with presence of ASCVD (Odds ratio per 1-SD increase, 0.37;95% CI, 0.15 – 0.86; <i>P</i>=0.0252).<b> </b></p><p><b>Conclusion: </b>The degree of lipid deposition in the AT of FH patients could be assessed by its thickness as well as its softness. AT softness is not only useful in diagnosing FH but is also associated with the severity of carotid atherosclerosis and presence of ASCVD. In addition, these findings suggest that AT softness would be helpful in risk assessment for FH patients.</p>

    DOI: 10.5551/jat.63151

    PubMed

  15. Circulating Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects

    Yu Kataoka, Mariko Harada-Shiba, Mika Hori, Makoto Watanabe, Yoshihiro Kokubo, Teruo Noguchi, Satoshi Yasuda, Yoshihiro Miyamoto

    JACC: Asia   Vol. 1 ( 3 ) page: 360 - 368   2021.12

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) circulates as mature and furin-cleaved forms, which differ in their properties to degrade low-density lipoprotein (LDL) receptors. Objectives: In this study, we sought to investigate whether PCSK9 subtypes associate with atherosclerotic cardiovascular events. Methods: We investigated 1,436 statin-naive Japanese subjects without any cardiovascular disease in the Suita Study, an epidemiologic Japanese cohort study. Total, mature, and furin-cleaved PCSK9 levels were measured by means of enzyme-linked immunosorbent assay. The occurrence of coronary and stroke events were compared in subjects stratified by PCSK9 level tertile. Results: Total, mature, and furin-cleaved PCSK9 levels were associated with non–high-density lipoprotein cholesterol (all P < 0.001) and systolic blood pressure (P = 0.001, P = 0.004, and P < 0.001, respectively). Furthermore, only furin-cleaved PCSK9 level was correlated to high-sensitivity C-reactive protein (hs-CRP) (P < 0.001). During the 13.6-year observational period, furin-cleaved PCSK9 level predicted a greater likelihood of experiencing coronary events (tertile 2: hazard ratio [HR]: 2.84 [95% confidence interval [CI]: 1.21-6.65; P = 0.01]; tertile 3: HR: 2.81 [95% CI: 1.17-6.74; P = 0.02]), but not stroke (tertile 2: HR: 1.31 [95% CI: 0.72-2.40; P = 0.36]; tertile 3: HR: 1.27 [95% CI: 0.68-2.38; P = 0.44]). Total and mature PCSK9 levels were not associated with coronary events (total PCSK9: tertile 2: HR: 1.35 [95% CI: 0.68-2.68; P = 0.39]; tertile 3: HR: 1.13 [95% CI: 0.54-2.34; P = 0.73]; mature PCSK9: tertile 2: HR: 1.02 [95% CI: 0.52-2.02; P = 0.93]; tertile 3: HR: 0.96 [95% CI: 0.47-1.95; P = 0.92]) and stroke events (total PCSK9: tertile 2: HR: 0.90 [95% CI: 0.50-1.61; P = 0.72]; tertile 3: HR: 0.99 [95% CI:0.54-1.80; P = 0.97]; mature PCSK9: tertile 2: HR: 0.86 [95% CI: 0.47-1.57; P = 0.63]; tertile 3: HR: 1.11 [95% CI: 0.61-1.99; P = 0.72]), respectively. Conclusions: Furin-cleaved but not total and mature PCSK9 was associated with both LDL cholesterol and hs-CRP and predicted future coronary events in the primary prevention settings. Our findings provide pathophysiological insights into the properties of PCSK9 subtypes in association with coronary events.

    DOI: 10.1016/j.jacasi.2021.09.003

    Scopus

  16. 家族性高コレステロール血症におけるRNF213 p.R4810K多型の効果

    野田 浩太郎, 服部 頼都, 堀 美香, 田中 総人, 斯波 真理子, 猪原 匡史

    脳循環代謝   Vol. 33 ( 1 ) page: 86 - 86   2021.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:(一社)日本脳循環代謝学会  

  17. Switching from lipoprotein apheresis to evolocumab in FH siblings on hemodialysis: case reports and discussion.

    Takeo Ishii, Masatsune Ogura, Haruka Nakamori, Mika Hori, Mariko Harada-Shiba, Kouichi Tamura, Kunio Oyama

    CEN case reports   Vol. 10 ( 4 ) page: 592 - 597   2021.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Familial hypercholesterolemia (FH) and chronic kidney disease, especially end-stage renal disease (ESRD), are common and put patients at a high risk of developing atherosclerotic cardiovascular disease (ASCVD). ESRD concomitant with FH may further increase the risk of ASCVD. Achieving target levels of low-density lipoprotein cholesterol (LDL-C) is difficult owing to the limitations of statin administration due to its side effects in ESRD. Therefore, some FH patients with ESRD require lipoprotein apheresis for the prevention of secondary ASCVD events. Although proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors may offer a safe and effective option for lowering lipid levels in such patients, no guidelines are available for their use. Here, we report the case of two male siblings with FH in secondary prevention undergoing hemodialysis combined with PCSK9 inhibitor treatment. The siblings, who showed a heterozygous c.1846-1G>A mutation in the LDLR gene, underwent hemodialysis. In combination with the lipoprotein apheresis, siblings were administered evolocumab, a PCSK9 inhibitor. Both the siblings had coronary artery disease, diabetes, and ESRD, and received hemodialysis. Their LDL-C levels did not reach the target values despite administering statin, ezetimibe, and biweekly lipoprotein apheresis. On the introduction of evolocumab treatment, their LDL-C levels were significantly reduced without any adverse effects, resulting in successful withdrawal from lipoprotein apheresis therapy. Although the effects of switching from lipoprotein apheresis to PCSK9 inhibitors for cardiovascular protection remain unclear in FH patients with and without ESRD, our case report will be helpful in guiding future therapeutic decisions.

    DOI: 10.1007/s13730-021-00605-x

    Scopus

    PubMed

  18. Current Diagnosis and Management of Abetalipoproteinemia. Reviewed

    Takahashi M, Okazaki H, Ohashi K, Ogura M, Ishibashi S, Okazaki S, Hirayama S, Hori M, Matsuki K, Yokoyama S, Harada-Shiba M

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 10 ) page: 1009 - 1019   2021.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:一般社団法人 日本動脈硬化学会  

    <p>Abetalipoproteinemia (ABL) is a rare autosomal recessive disorder caused by biallelic pathogenic mutations in the <i>MTTP</i> gene. Deficiency of microsomal triglyceride transfer protein (MTTP) abrogates the assembly of apolipoprotein (apo) B-containing lipoprotein in the intestine and liver, resulting in malabsorption of fat and fat-soluble vitamins and severe hypolipidemia. Patients with ABL typically manifest steatorrhea, vomiting, and failure to thrive in infancy. The deficiency of fat-soluble vitamins progressively develops into a variety of symptoms later in life, including hematological (acanthocytosis, anemia, bleeding tendency, etc.), neuromuscular (spinocerebellar ataxia, peripheral neuropathy, myopathy, etc.), and ophthalmological symptoms (e.g., retinitis pigmentosa). If left untreated, the disease can be debilitating and even lethal by the third decade of life due to the development of severe complications, such as blindness, neuromyopathy, and respiratory failure. High dose vitamin supplementation is the mainstay for treatment and may prevent, delay, or alleviate the complications and improve the prognosis, enabling some patients to live to the eighth decade of life. However, it cannot fully prevent or restore impaired function. Novel therapeutic modalities that improve quality of life and prognosis are awaited. The aim of this review is to 1) summarize the pathogenesis, clinical signs and symptoms, diagnosis, and management of ABL, and 2) propose diagnostic criteria that define eligibility to receive financial support from the Japanese government for patients with ABL as a rare and intractable disease. In addition, our diagnostic criteria and the entry criterion of low-density lipoprotein cholesterol (LDL-C) <15 mg/dL and apoB <15 mg/dL can be useful in universal or opportunistic screening for the disease. Registry research on ABL is currently ongoing to better understand the disease burden and unmet needs of this life-threatening disease with few therapeutic options. </p>

    DOI: 10.5551/jat.RV17056

    PubMed

  19. Current Diagnosis and Management of Primary Chylomicronemia. Reviewed

    Okazaki H, Gotoda T, Ogura M, Ishibashi S, Inagaki K, Daida H, Hayashi T, Hori M, Masuda D, Matsuki K, Yokoyama S, Harada-Shiba M

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 9 ) page: 883 - 904   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Atherosclerosis and Thrombosis  

    Primary chylomicronemia (PCM) is a rare and intractable disease characterized by marked accumulation of chylomicrons in plasma. The levels of plasma triglycerides (TGs) typically range from 1,000 - 15,000 mg/dL or higher. PCM is caused by defects in the lipoprotein lipase (LPL) pathway due to genetic mutations, autoantibodies, or unidentified causes. The monogenic type is typically inherited as an autosomal recessive trait with loss-offunction mutations in LPL pathway genes (LPL, LMF1, GPIHBP1, APOC2, and APOA5). Secondary/environmental factors (diabetes, alcohol intake, pregnancy, etc.) often exacerbate hypertriglyceridemia (HTG). The signs, symptoms, and complications of chylomicronemia include eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and acute pancreatitis with onset as early as in infancy. Acute pancreatitis can be fatal and recurrent episodes of abdominal pain may lead to dietary fat intolerance and failure to thrive. The main goal of treatment is to prevent acute pancreatitis by reducing plasma TG levels to at least less than 500-1,000 mg/dL. However, current TG-lowering medications are generally ineffective for PCM. The only other treatment options are modulation of secondary/environmental factors. Most patients need strict dietary fat restriction, which is often difficult to maintain and likely affects their quality of life. Timely diagnosis is critical for the best prognosis with currently available management, but PCM is often misdiagnosed and undertreated. The aim of this review is firstly to summarize the pathogenesis, signs, symptoms, diagnosis, and management of PCM, and secondly to propose simple diagnostic criteria that can be readily translated into general clinical practice to improve the diagnostic rate of PCM. In fact, these criteria are currently used to define eligibility to receive social support from the Japanese government for PCM as a rare and intractable disease. Nevertheless, further research to unravel the molecular pathogenesis and develop effective therapeutic modalities is warranted. Nationwide registry research on PCM is currently ongoing in Japan with the aim of better understanding the disease burden as well as the unmet needs of this life-threatening disease with poor therapeutic options.

    DOI: 10.5551/jat.RV17054

    Scopus

    PubMed

  20. Can We Clarify the Causative Gene/Variants Underlying Familial Hypercholesterolemia and Improve Genetic Diagnosis Rate? Invited Reviewed

    Hori M

    Journal of atherosclerosis and thrombosis     2021.8

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:一般社団法人 日本動脈硬化学会  

    DOI: 10.5551/jat.ED184

    PubMed

  21. Current Diagnosis and Management of Tangier Disease. Reviewed

    Koseki M, Yamashita S, Ogura M, Ishigaki Y, Ono K, Tsukamoto K, Hori M, Matsuki K, Yokoyama S, Harada-Shiba M

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 8 ) page: 802 - 810   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Atherosclerosis and Thrombosis  

    Tangier disease is a genetic disorder characterized by an absence or extremely low level of high-density lipoprotein (HDL)-cholesterol (HDL-C). It is caused by a dysfunctional mutation of the ATP-binding cassette transporter A1 (ABCA1) gene, the mandatory gene for generation of HDL particles from cellular cholesterol and phospholipids, and it appears in an autosomal recessive hereditary profile. To date, 35 cases have been reported in Japan and 109 cases outside Japan. With dysfunctional mutations in both alleles (homozygotes or compound heterozygotes), the HDL-C level is mostly less than 5 mg/dL and there is 10 mg/dL or less of apolipoprotein A-I (apoA-I), the major protein component of HDL. In patients with Tangier disease, major physical findings are orange-colored pharyngeal tonsils, hepatosplenomegaly, corneal opacity, lymphadenopathy, and peripheral neuropathy. Although patients tend to have decreased low-density lipoprotein (LDL)-cholesterol (LDL-C) levels, premature coronary artery disease is frequently observed. No specific curative treatment is currently available, so early identification of patients and preventing atherosclerosis development are crucial. Management of risk factors other than low HDL-C is also important, such as LDL-C levels, hypertension and smoking. Additionally, treatment for glucose intolerance might be required because impaired insulin secretion from pancreatic beta cells has occasionally been reported.

    DOI: 10.5551/jat.RV17053

    Scopus

    PubMed

  22. Diagnosis and Management of Sitosterolemia 2021. Reviewed

    Tada H, Nomura A, Ogura M, Ikewaki K, Ishigaki Y, Inagaki K, Tsukamoto K, Dobashi K, Nakamura K, Hori M, Matsuki K, Yamashita S, Yokoyama S, Kawashiri MA, Harada-Shiba M

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 8 ) page: 791 - 801   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Atherosclerosis and Thrombosis  

    Sitosterolemia is an inherited metabolic disorder characterized by increased levels of plant sterols, such as sitosterol. This disease is caused by loss-of-function genetic mutations in ATP-binding cassette (ABC) subfamily G member 5 or member 8 (ABCG5 or ABCG8, respectively), both of which play important roles in selective excretion of plant sterols from the liver and intestine, leading to failure to prevent absorption of food plant sterols. This disorder has been considered to be extremely rare. However, accumulated clinical data as well as genetics suggest the possibility of a much higher prevalence. Its clinical manifestations resemble those observed in patients with familial hypercholesterolemia (FH), including tendon xanthomas, hyper LDL-cholesterolemia, and premature coronary atherosclerosis. We provide an overview of this recessive genetic disease, diagnostic as well as therapeutic tips, and the latest diagnostic criteria in Japan.

    DOI: 10.5551/jat.RV17052

    Scopus

    PubMed

  23. Homozygous Familial Hypercholesterolemia. Reviewed

    Nohara A, Tada H, Ogura M, Okazaki S, Ono K, Shimano H, Daida H, Dobashi K, Hayashi T, Hori M, Matsuki K, Minamino T, Yokoyama S, Harada-Shiba M

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 7 ) page: 665 - 678   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Atherosclerosis and Thrombosis  

    Familial hypercholesterolemia (FH) is an inherited disorder with retarded clearance of plasma LDL caused by mutations of the genes involved in the LDL receptor-mediated pathway and most of them exhibit autosomal dominant inheritance. Homozygotes of FH (HoFH) may have plasma LDL-C levels, which are at least twice as high as those of heterozygous FH (HeFH) and therefore four times higher than normal levels. Prevalence of HoFH had been estimated as 1 in 1,000,000 before but more recent genetic analysis surveys predict 1 in 170,000 to 300,000. Since LDL receptor activity is severely impaired, HoFH patients do not or very poorly respond to medications to enhance activity, such as statins, and have a poorer prognosis compared to HeFH. HoFH should therefore be clinically distinguished from HeFH. Thorough family studies and genetic analysis are recommended for their accurate diagnosis. Fatal cardiovascular complications could develop even in the first decade of life for HoFH, so aggressive lipid-lowering therapy should be initiated as early as possible. Direct removal of plasma LDL by lipoprotein apheresis has been the principal measure for these patients. However, this treatment alone may not achieve stable LDL-C target levels and combination with drugs should be considered. The lipid-lowering effects of statins and PCSK9 inhibitors substantially vary depending on the remaining LDL receptor activity of individual patients. On the other hand, the action an MTP inhibitor is independent of LDL receptor activity, and it is effective in most HoFH cases. This review summarizes the key clinical issues of HoFH as well as insurance coverage available under the Japanese public healthcare system.

    DOI: 10.5551/jat.RV17050

    Scopus

    PubMed

  24. Current Status of Familial LCAT Deficiency in Japan. Reviewed

    Kuroda M, Bujo H, Yokote K, Murano T, Yamaguchi T, Ogura M, Ikewaki K, Koseki M, Takeuchi Y, Nakatsuka A, Hori M, Matsuki K, Miida T, Yokoyama S, Wada J, Harada-Shiba M

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 7 ) page: 679 - 691   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of Atherosclerosis and Thrombosis  

    Lecithin cholesterol acyltransferase (LCAT) is a lipid-modification enzyme that catalyzes the transfer of the acyl chain from the second position of lecithin to the hydroxyl group of cholesterol (FC) on plasma lipoproteins to form cholesteryl acylester and lysolecithin. Familial LCAT deficiency is an intractable autosomal recessive disorder caused by inherited dysfunction of the LCAT enzyme. The disease appears in two different phenotypes depending on the position of the gene mutation: familial LCAT deficiency (FLD, OMIM 245900) that lacks esterification activity on both HDL and ApoB-containing lipoproteins, and fish-eye disease (FED, OMIM 136120) that lacks activity only on HDL. Impaired metabolism of cholesterol and phospholipids due to LCAT dysfunction results in abnormal concentrations, composition and morphology of plasma lipoproteins and further causes ectopic lipid accumulation and/or abnormal lipid composition in certain tissues/cells, and serious dysfunction and complications in certain organs. Marked reduction of plasma HDL-cholesterol (HDL-C) and corneal opacity are common clinical manifestations of FLD and FED. FLD is also accompanied by anemia, proteinuria and progressive renal failure that eventually requires hemodialysis. Replacement therapy with the LCAT enzyme should prevent progression of serious complications, particularly renal dysfunction and corneal opacity. A clinical research project aiming at gene/cell therapy is currently underway.

    DOI: 10.5551/jat.RV17051

    Scopus

    PubMed

  25. Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene. Reviewed

    Tada H, Hori M, Matsuki K, Ogura M, Nohara A, Kawashiri MA, Harada-Shiba M

    Journal of atherosclerosis and thrombosis     2021.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:一般社団法人 日本動脈硬化学会  

    <p><b>Aim: </b>The 2017 Japan Atherosclerosis Society (JAS) familial hypercholesterolemia (FH) criteria adopt a cut-off value of ≥ 9 mm of Achilles tendon thickness (ATT) detected by X-ray as one of the three key items. This threshold was determined based on an old data evaluating the ATT of 36 non-FH individuals that was published in 1977. Although the specificity of these clinical criteria is extremely high due to a strict threshold, there are a significant number of patients with FH whose ATT <9 mm. We aimed to determine a cut-off value of ATT detected by X-ray to differentiate FH and non-FH based on genetic diagnosis.<b> </b></p><p><b>Methods:</b> The individuals (male/female=486/501) with full assessments of genetic analyses for FH-genes (<i>LDLR</i> and <i>PCSK9</i>), serum lipids, and ATT detected by X-ray at the Kanazawa University Hospital and National Cerebral and Cardiovascular Center Research Institute were included in this study. Receiver operating characteristic (ROC) analyses were conducted to determine a better cut-off value of ATT that predicts the pathogenic mutation of FH.<b> </b></p><p><b>Results: </b>The ROC analyses revealed that the best cut-off values of ATT are 7.6 mm for male and 7.0 mm for female, with the sensitivities/specificities of 0.83/0.83 for male and 0.86/0.85 for female, respectively. If the thresholds of ATT of 8.0/7.5 mm and 7.5/7.0 mm were applied to the diagnosis of male/female FH, the sensitivities/specificities predicting the pathogenic mutation of FH by the 2017 JAS FH clinical criteria would be 0.82/0.90 and 0.85/0.88, respectively.<b> </b></p><p><b>Conclusions: </b>These results suggest that the cut-off value of ATT detected by X-ray is obviously lower than 9.0 mm, which was adopted by the 2017 JAS FH clinical criteria.</p>

    DOI: 10.5551/jat.62869

    PubMed

  26. Achilles Tendon Softness as a New Tool for Diagnosing Familial Hypercholesterolemia. Reviewed International journal

    Masahito Michikura, Masatsune Ogura, Mika Hori, Kenji Furuta, Kiminori Hosoda, Mariko Harada-Shiba

    JACC. Cardiovascular imaging   Vol. 14 ( 7 ) page: 1483 - 1485   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jcmg.2021.01.033

    PubMed

  27. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy. Reviewed

    Kuyama N, Kataoka Y, Takegami M, Nishimura K, Harada-Shiba M, Hori M, Ogura M, Otsuka F, Asaumi Y, Noguchi T, Tsujita K, Yasuda S

    Journal of the American Heart Association   Vol. 10 ( 11 ) page: e019525   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of the American Heart Association  

    BACKGROUND: Statin-mediated efficacy of lowering low-density lipoprotein (LDL) cholesterol varies in each individual, and its diminished response is associated with worse outcomes. However, there is no established approach to predict hyporesponse to statins. PCSK9 (proprotein convertase subxilisin/kexin type 9) is a serine-protease associated with LDL metabolism, which circulates as mature and furin-cleaved PCSK9. Since mature PCSK9 more potently degrades the LDL receptor, its evaluation may enable the identification of statin hyporesponders. METHODS AND RESULTS: We analyzed 101 statin-naive patients with coronary artery disease who commenced a statin. PCSK9 subtypes at baseline and 1 month after statin use were measured by ELISA. Hyporesponse to statins was defined as a percent reduction in LDL cholesterol <15%. The relationship between each PCSK9 subtype level and hyporesponse to statins was investigated. Statins significantly lowered LDL cholesterol level (percent reduction, 40%±21%), whereas 11% of study participants exhibited a hyporeseponse to statins. Multivariable logistic regression analysis demonstrated that baseline mature PCSK9 level was an independent predictor for hyporesponse to statins even after adjusting clinical characteristics (mature PCSK9 per 10-ng/mL increase: odds ratio [OR], 1.12; 95% CI, 1.01–1.24 [P=0.03]), whereas furin-cleaved level was not (per 10-ng/mL increase: OR, 1.37; 95% CI, 0.73–2.58 [P=0.33]). Receiver operating characteristic curve analysis identified mature PCSK9 level of 228 ng/mL as an optimal cutoff to predict hyporesponse to statins (area under the curve, 0.73 [sensitivity, 0.91; specificity, 0.56]). CONCLUSIONS: Baseline mature PCSK9 level >228 ng/mL is associated with hyporesponse to statins. This finding suggests that mature PCSK9 might be a potential determinant of hyporesponse to statins.

    DOI: 10.1161/JAHA.120.019525

    Scopus

    PubMed

  28. A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the PCSK9 and ABCG5 Genes and Type I CD36 Deficiency. Reviewed

    Ryo Nishikawa, Masato Furuhashi, Mika Hori, Masatsune Ogura, Mariko Harada-Shiba, Takeshi Okada, Masahiro Koseki, Takeshi Kujiraoka, Hiroaki Hattori, Ryosuke Ito, Atsuko Muranaka, Nobuaki Kokubu, Tetsuji Miura

    Journal of atherosclerosis and thrombosis     2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 56-year-old postmenopausal woman with out-of-hospital cardiac arrest caused by acute myocardial infraction was successfully resuscitated by intensive treatments and recovered without any neurological disability. She was diagnosed as having familial hypercholesterolemia (FH) based on a markedly elevated low-density lipoprotein cholesterol (LDL-C) level and family history of premature coronary artery disease. Genetic testing in her family members showed that a variant of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (c.2004C>A, p.S668R), which had been previously reported as having uncertain significance, was associated with FH, indicating that the variant is a potential candidate for the FH phenotype. Next-generation sequencing analysis for the proband also showed that there was a heterozygous mutation of the ATP-binding cassette sub-family G member 5 (ABCG5) gene (c.1166G>A, R389H), which has been reported to increase LDL-C level and the risk of cardiovascular disease. She was also diagnosed as having type 1 CD36 deficiency based on a lack of myocardial uptake of 123 I-labeled 15-(p-iodophenyl)-3-R,S-methyl-pentadecanoic acid in scintigraphy and the absence of CD36 antigen in both monocytes and platelets in flow cytometry. She had a homozygous mutation of the CD36 gene (c.1126-5_1127delTTTAGAT), which occurs in a canonical splice site (acceptor) and is predicted to disrupt or distort the normal gene product. To our knowledge, this is the first report of a heterozygous FH phenotype caused by possibly oligogenic variants of the PCSK9 and ABCG5 genes complicated with type I CD36 deficiency caused by a novel homozygous mutation. Both FH phenotype and CD36 deficiency might have caused extensive atherosclerosis, leading to acute myocardial infarction in the present case.

    DOI: 10.5551/jat.58909

    PubMed

  29. Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia. Reviewed International journal

    Takahito Doi, Mika Hori, Mariko Harada-Shiba, Yu Kataoka, Daisuke Onozuka, Kunihiro Nishimura, Ryo Nishikawa, Kosuke Tsuda, Masatsune Ogura, Cheol Son, Yoshihiro Miyamoto, Teruo Noguchi, Hiroaki Shimokawa, Satoshi Yasuda

    Journal of the American Heart Association   Vol. 10 ( 4 ) page: e018263 - 11   2021.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Background Patients with familial hypercholesterolemia who harbored both low-density lipoprotein receptor (LDLR) and PCSK9 (proprotein convertase subtilisin/kexin type 9) gene variants exhibit severe phenotype associated with substantially high levels of low-density lipoprotein cholesterol. In this study, we investigated the cardiovascular outcomes in patients with both LDLR and PCSK9 gene variants. Methods and Results A total of 232 unrelated patients with LDLR and/or PCSK9 gene variants were stratified as follows: patients with LDLR and PCSK9 (LDLR/PCSK9) gene variants, patients with LDLR gene variant, and patients with PCSK9 gene variant. Clinical demographics and the occurrence of primary outcome (nonfatal myocardial infarction) were compared. The observation period of primary outcome started at the time of birth and ended at the time of the first cardiac event or the last visit. Patients with LDLR/PCSK9 gene variants were identified in 6% of study patients. They had higher levels of low-density lipoprotein cholesterol (P=0.04) than those with LDLR gene variants. On multivariate Cox regression model, they experienced a higher incidence of nonfatal myocardial infarction (hazard ratio, 4.62; 95% CI, 1.66-11.0; P=0.003 versus patients with LDLR gene variant). Of note, risk for nonfatal myocardial infarction was greatest in male patients with LDLR/PCSK9 gene variants compared with those with LDLR gene variant (86% versus 24%; P<0.001). Conclusions Patients with LDLR/PCSK9 gene variants were high-risk genotype associated with atherogenic lipid profiles and worse cardiovascular outcomes. These findings underscore the importance of genetic testing to identify patients with LDLR/PCSK9 gene variants, who require more stringent antiatherosclerotic management.

    DOI: 10.1161/JAHA.120.018263

    Scopus

    PubMed

  30. Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

    Shingo Koyama, Yoshiki Sekijima, Masatsune Ogura, Mika Hori, Kota Matsuki, Takashi Miida, Mariko Harada-Shiba

    Journal of atherosclerosis and thrombosis   Vol. 28 ( 9 ) page: 905 - 925   2021

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japan Atherosclerosis Society  

    Cerebrotendinous xanthomatosis (CTX) is an autosomal recessive lipid storage disorder caused by mutations in the CYP27A1 gene, which encodes the mitochondrial enzyme sterol 27-hydroxylase. Decreased sterol 27-hydroxylase activity results in impaired bile acid synthesis, leading to reduced production of bile acids, especially chenodeoxycholic acid (CDCA), as well as elevated serum cholestanol and urine bile alcohols. The accumulation of cholestanol and cholesterol mainly in the brain, lenses, and tendons results in the characteristic clinical manifestations of CTX. Clinical presentation is characterized by systemic symptoms including neonatal jaundice or cholestasis, refractory diarrhea, juvenile cataracts, tendon xanthomas, osteoporosis, coronary heart disease, and a broad range of neuropsychiatric manifestations. The combinations of symptoms vary from patient to patient and the presenting symptoms, especially in the early disease phase, may be nonspecific, which leads to a substantial diagnostic delay or underdiagnosis. Replacement of CDCA has been approved as a first-line treatment for CTX, and can lead to biochemical and clinical improvements. However, the effect of CDCA treatment is limited once significant neuropsychiatric manifestations are established. The age at diagnosis and initiation of CDCA treatment correlate with the prognosis of patients with CTX. Therefore, early diagnosis and subsequent treatment initiation are essential.

    DOI: 10.5551/jat.RV17055

    Web of Science

    Scopus

    PubMed

    CiNii Research

  31. Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis. Reviewed

    Matsuura T, Maru Y, Izumiya M, Hoshi D, Kato S, Ochiai M, Hori M, Yamamoto S, Tatsuno K, Imai T, Aburatani H, Nakajima A, Hippo Y

    Carcinogenesis   Vol. 41 ( 4 ) page: 490-501   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1093/carcin/bgz122

    PubMed

  32. The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G&gt;A: p.(Arg3527Gln). Reviewed

        2020.5

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jacl.2020.05.007

    PubMed

  33. A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. Reviewed

    Tada H, Hori M, Nomura A, Hosomichi K, Nohara A, Kawashiri MA, Harada-Shiba M

    Journal of clinical lipidology   Vol. 14 ( 3 ) page: 346-351.e9   2020.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jacl.2020.03.002

    PubMed

  34. The benign c.344G &gt; A: p.(Arg115His) variant in the LDLR gene interpreted from a pedigree-based genetic analysis of familial hypercholesterolemia. Reviewed

    Hori M, Takahashi A, Son C, Ogura M, Harada-Shiba M

    Lipids in health and disease   Vol. 19 ( 1 ) page: 62   2020.4

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12944-020-01252-4

    PubMed

  35. Detection of the benign c.2579C&gt;T (p.A860V) variant of the LDLR gene in a pedigree-based genetic analysis of familial hypercholesterolemia. Reviewed

    Hori M, Miyauchi E, Son C, Harada-Shiba M

    Journal of clinical lipidology   Vol. 13 ( 2 ) page: 335-339   2019.3

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jacl.2019.01.004

    PubMed

  36. Discontinuation of LDL apheresis with evolocumab in an FH patient with a duplication of exon 2-6 in the <i>LDLR</i> gene. Reviewed

    Nose D, Hori M, Miyamoto Y, Imaizumi S, Harada-Shiba M, Saku K, Miura SI

    Journal of cardiology cases   Vol. 19 ( 2 ) page: 55-58   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jccase.2018.10.005

    PubMed

  37. Pharmaceutical Research for Inherited Metabolic Disorders of the Liver Using Human Induced Pluripotent Stem Cell and Genome Editing Technologies.

    Yamashita T, Takayama K, Hori M, Harada-Shiba M, Mizuguchi H

    Biological & pharmaceutical bulletin   Vol. 42 ( 3 ) page: 312-318   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1248/bpb.b18-00544

    PubMed

  38. No enhancing effects of plasmid-specific histone acetyltransferase recruitment system on transgene expression in vivo. Reviewed

    Suzuki T, Wakao Y, Watanabe T, Hori M, Ikeda Y, Tsuchiya H, Kogure K, Harada-Shiba M, Fujimuro M, Kamiya H

    Nucleosides, nucleotides & nucleic acids   Vol. 38 ( 12 ) page: 942-949   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1080/15257770.2019.1638514

    PubMed

  39. Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans. Reviewed

    Takahashi M, Hori M, Ishigamori R, Mutoh M, Imai T, Nakagama H

    Cancer science   Vol. 109 ( 10 ) page: 3013-3023   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13766

    PubMed

  40. Activated Ductal Proliferation Induced by <i>N</i>-Nitroso<i>bis</i> (2-oxopropyl)amine in Fat-infiltrated Pancreas of KK-<i>A<sup>y</sup></i> Mice. Reviewed

    Hori M, Mutoh M, Ishigamori R, Imai T, Takahashi M

    In vivo (Athens, Greece)   Vol. 32 ( 3 ) page: 499-505   2018.5

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/invivo.11267

    PubMed

  41. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. Reviewed

    Hasegawa Y, Hori M, Nakagami T, Harada-Shiba M, Uchigata Y

    Journal of clinical lipidology   Vol. 12 ( 1 ) page: 62-69.e1   2018.1

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jacl.2017.11.006

    PubMed

  42. Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation. Reviewed

    Shirahama R, Ono T, Nagamatsu S, Sueta D, Takashio S, Chitose T, Fujisue K, Sakamoto K, Yamamoto E, Izumiya Y, Kaikita K, Hokimoto S, Hori M, Harada-Shiba M, Kajiwara I, Ogawa H, Tsujita K

    Internal medicine (Tokyo, Japan)   Vol. 57 ( 24 ) page: 3551-3557   2018

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2169/internalmedicine.1060-18

    PubMed

  43. Achilles Tendon Ultrasonography for Diagnosis of Familial Hypercholesterolemia Among Japanese Subjects. Reviewed

    Michikura M, Ogura M, Yamamoto M, Sekimoto M, Fuke C, Hori M, Arai K, Kihara S, Hosoda K, Yanagi K, Harada-Shiba M

    Circulation journal : official journal of the Japanese Circulation Society   Vol. 81 ( 12 ) page: 1879-1885   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1253/circj.CJ-17-0041

    PubMed

  44. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. Reviewed

    Kataoka Y, Harada-Shiba M, Nakao K, Nakashima T, Kawakami S, Fujino M, Kanaya T, Nagai T, Tahara Y, Asaumi Y, Hori M, Ogura M, Goto Y, Noguchi T, Yasuda S

    Journal of clinical lipidology   Vol. 11 ( 2 ) page: 413-421.e3   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jacl.2017.01.005

    PubMed

  45. Evaluation of the degree of pancreatic fatty infiltration by area-based assessment of CT images: comparison with histopathology-based and CT attenuation index-based assessments. Reviewed

    Hori M, Onaya H, Hiraoka N, Yamaji T, Kobayashi H, Takahashi M, Mutoh M, Shimada K, Nakagama H

    Japanese journal of radiology   Vol. 34 ( 10 ) page: 667 - 676   2016.10

     More details

    Authorship:Lead author  

    DOI: 10.1007/s11604-016-0572-0

    PubMed

  46. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Reviewed

    Ogura M, Hori M, Harada-Shiba M

    Arteriosclerosis, thrombosis, and vascular biology   Vol. 36 ( 1 ) page: 181 - 8   2016.1

  47. Possible involvement of pancreatic fatty infiltration in pancreatic carcinogenesis Reviewed

    Hori M, Mutoh M, Imai T, Nakagama H, Takahashi M

    Journal of Pancreas   Vol. 17   page: 166 - 175   2016

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  48. Association of pancreatic Fatty infiltration with pancreatic ductal adenocarcinoma. Reviewed

    Hori M, Takahashi M, Hiraoka N, Yamaji T, Mutoh M, Ishigamori R, Furuta K, Okusaka T, Shimada K, Kosuge T, Kanai Y, Nakagama H

    Clinical and translational gastroenterology   Vol. 5   page: e53   2014.3

     More details

    Authorship:Lead author  

    DOI: 10.1038/ctg.2014.5

    PubMed

  49. Invasive ductal carcinoma developing in pancreas with severe Fatty infiltration. Reviewed

    Hori M, Onaya H, Takahashi M, Hiraoka N, Mutoh M, Kosuge T, Nakagama H

    Pancreas   Vol. 41 ( 7 ) page: 1137 - 9   2012.10

     More details

    Authorship:Lead author  

    DOI: 10.1097/MPA.0b013e318252ea08

    PubMed

  50. Enhancement of carcinogenesis and fatty infiltration in the pancreas in N-nitrosobis(2-oxopropyl)amine-treated hamsters by high-fat diet. Reviewed

    Hori M, Kitahashi T, Imai T, Ishigamori R, Takasu S, Mutoh M, Sugimura T, Wakabayashi K, Takahashi M

    Pancreas   Vol. 40 ( 8 ) page: 1234 - 40   2011.11

     More details

    Authorship:Lead author  

    DOI: 10.1097/MPA.0b013e318220e742

    PubMed

  51. Mutagenicity of secondary oxidation products of 8-oxo-7,8-dihydro-2'-deoxyguanosine 5'-triphosphate (8-hydroxy-2'- deoxyguanosine 5'-triphosphate). Reviewed

    Hori M, Suzuki T, Minakawa N, Matsuda A, Harashima H, Kamiya H

    Mutation research   Vol. 714 ( 1-2 ) page: 11 - 6   2011.9

     More details

    Authorship:Lead author  

    DOI: 10.1016/j.mrfmmm.2011.05.015

    PubMed

  52. Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease. Reviewed

    Takahashi M, Hori M, Mutoh M, Wakabayashi K, Nakagama H

    Cancers   Vol. 3 ( 1 ) page: 582 - 602   2011.2

     More details

  53. Suppression of mutagenesis by 8-hydroxy-2 '-deoxyguanosine 5 '-triphosphate (7,8-dihydro-8-oxo-2 '-deoxyguanosine 5 '-triphosphate) by human MTH1, MTH2, and NUDT5 Reviewed

    Hori Mika, Satou Kazuya, Harashima Hideyoshi, Kamiya Hiroyuki

    FREE RADICAL BIOLOGY AND MEDICINE   Vol. 48 ( 9 ) page: 1197 - 1201   2010.5

     More details

  54. Early and enhanced development of N-nitrosobis(2-oxopropyl)amine-induced hamster pancreatic adenocarcinomas by high-fat diet Reviewed

    Takahashi Mami, Hori Mika, Kitahashi Tsukasa, Imai Toshio, Ishigamori Rikako, Takasu Shinji, Mutoh Michihiro, Sugimura Takashi, Wakabayashi Keiji

    CANCER RESEARCH   Vol. 70   2010.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1158/1538-7445.AM10-2478

    Web of Science

  55. NUDT5 hydrolyzes oxidized deoxyribonucleoside diphosphates with broad substrate specificity. Reviewed

    Kamiya H, Hori M, Arimori T, Sekiguchi M, Yamagata Y, Harashima H

    DNA repair   Vol. 8 ( 10 ) page: 1250 - 4   2009.10

  56. Involvement of specialized DNA polymerases in mutagenesis by 8-hydroxy-dGTP in human cells. Reviewed

    Satou K, Hori M, Kawai K, Kasai H, Harashima H, Kamiya H

    DNA repair   Vol. 8 ( 5 ) page: 637 - 42   2009.5

     More details

    Authorship:Lead author  

    DOI: 10.1016/j.dnarep.2008.12.009

    PubMed

  57. Roles of specialized DNA polymerases in mutagenesis by oxidized guanine. Reviewed

    Kamiya H, Satou K, Hori M, Yamaguchi A, Harashima H

    Nucleic acids symposium series (2004)   ( 53 ) page: 223 - 4   2009

     More details

  58. UvrA and UvrB enhance mutations induced by oxidized deoxyribonucleotides. Reviewed

    Hori M, Ishiguro C, Suzuki T, Nakagawa N, Nunoshiba T, Kuramitsu S, Yamamoto K, Kasai H, Harashima H, Kamiya H

    DNA repair   Vol. 6 ( 12 ) page: 1786 - 93   2007.12

     More details

    Authorship:Lead author  

    DOI: 10.1016/j.dnarep.2007.06.013

    PubMed

  59. Effects of overexpression and antisense RNA expression of Orf17, a MutT-type enzyme Reviewed

    Hori Mika, Asanuma Taketoshi, Inanami Osamu, Kuwabara Mikinori, Harashima Hideyoshi, Kamiya Hiroyuki

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   Vol. 29 ( 6 ) page: 1087 - 1091   2006.6

     More details

    Authorship:Lead author  

    Web of Science

  60. In vivo mutagenicities of damaged nucleotides produced by nitric oxide and ionizing radiation Reviewed

    Hori M, Ishiguro C, Harashima H, Kamiya H

    BIOLOGICAL & PHARMACEUTICAL BULLETIN   Vol. 28 ( 3 ) page: 520 - 522   2005.3

     More details

    Authorship:Lead author  

    Web of Science

  61. Dual hydrolysis of diphosphate and triphosphate derivatives of oxidized deoxyadenosine by Orf17 (NtpA), a MutT-type enzyme. Reviewed

    Hori M, Fujikawa K, Kasai H, Harashima H, Kamiya H

    DNA repair   Vol. 4 ( 1 ) page: 33 - 9   2005.1

     More details

    Authorship:Lead author  

    DOI: 10.1016/j.dnarep.2004.07.010

    PubMed

  62. Mutagenesis by damaged deoxyribonucleotides and its prevention by MutT-type hydrolyzing enzymes.

    Kamiya H, Satou K, Hori M, Iida E, Ishiguro C, Harashima H

    Nucleic acids symposium series (2004)   ( 48 ) page: 271 - 2   2004

     More details

▼display all

MISC 87

  1. 家族性高コレステロール血症と脳小血管病の重症化との関連についての検討

    村田 博朗, 服部 頼都, 堀 美香, 野田 浩太郎, 田中 聡人, 長井 篤, 山口 修平, 斯波 真理子, 猪原 匡史

    脳循環代謝   Vol. 34 ( 1 ) page: 96 - 96   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本脳循環代謝学会  

  2. 家族性高コレステロール血症における頭蓋内血管狭窄症と脳梗塞罹患率の疫学的調査研究

    野田 浩太郎, 服部 頼都, 堀 美香, 田中 聡人, 長井 篤, 山口 修平, 斯波 真理子, 猪原 匡史

    脳循環代謝   Vol. 34 ( 1 ) page: 94 - 94   2022.10

     More details

    Language:Japanese   Publisher:(一社)日本脳循環代謝学会  

  3. Polyvascular Atherosclerotic Diseaseのトピックス 家族性高コレステロール血症におけるPolyvascular diseaseの臨床像と治療介入の可能性

    舟橋 紗耶華, 片岡 有, 堀 美香, 小倉 正恒, 野口 暉夫, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 54回   page: 136 - 136   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  4. 家族性高コレステロール血症ヘテロ接合体におけるLDLR、PCSK9両遺伝子変異保有の予後への影響に関する検討

    土井 貴仁, 堀 美香, 斯波 真理子, 片岡 有, 小野塚 大介, 西村 邦宏, 西川 諒, 津田 浩佑, 小倉 正恒, 孫 徹, 宮本 恵宏, 野口 暉夫, 下川 宏明, 安田 聡

    日本動脈硬化学会総会プログラム・抄録集   Vol. 54回   page: 112 - 112   2022.7

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  5. 本邦特有PCSK9遺伝子変異の重症家族性高コレステロール血症の病態への寄与の解明

    堀 美香

    医科学応用研究財団研究報告   Vol. 39   page: 368 - 369   2022.2

     More details

    Language:Japanese   Publisher:(公財)鈴木謙三記念医科学応用研究財団  

  6. 本邦特有PCSK9遺伝子変異による家族性高コレステロール血症の重症化機序の解明

    堀 美香

    心臓   Vol. 53 ( 12 ) page: 1365 - 1365   2021.12

     More details

    Language:Japanese   Publisher:(公財)日本心臓財団  

  7. 家族性高コレステロール血症におけるRNF213 p.R4810K多型の効果

    野田 浩太郎, 服部 頼都, 堀 美香, 田中 総人, 斯波 真理子, 猪原 匡史

    脳循環代謝   Vol. 33 ( 1 ) page: 86 - 86   2021.11

     More details

    Language:Japanese   Publisher:(一社)日本脳循環代謝学会  

  8. PCSK9阻害薬がLDL-C低下に有効であった小児FHホモ接合体の一例

    松木 恒太, 小倉 正恒, 山本 雅, 堀 美香, 斯波 真理子

    The Lipid   Vol. 31 ( 1 ) page: 89 - 90   2020.4

     More details

    Language:Japanese   Publisher:(株)メディカルレビュー社  

  9. 父親の狭心症を契機に家族性高コレステロール血症と診断された1歳児

    永関 ひかる, 秋山 政晴, 堀 美香, 斯波 真理子, 井田 博幸, 宮田 市郎

    日本小児科学会雑誌   Vol. 124 ( 4 ) page: 704 - 708   2020.4

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

    1歳3ヵ月、男児。父親の脂質異常症と狭心症に加え、父方祖父の病歴から、産業医が医療機関受診を勧めたため当院へ受診となった。患児は無症状であったが、血液検査や遺伝子検査の結果から、家族性高コレステロール血症と診断された。食事指導を行うもLDLコレステロール(LDL-C)値の改善は認められなかったため、コレスチラミン製剤の内服を開始したところ、治療開始10ヵ月で総コレステロール(TC)と中性脂肪(TG)は共に245mg/dL、LDL-C値は194mg/dLに低下し、コントロール良好となった。目下は25ヵ月でTC、TGは249mg/dL、LDL-Cは185mg/dLで経過している。

  10. ヒトiPS細胞技術を用いた常染色体劣性高コレステロール血症の病態再現

    冨田 純矢, 高山 和雄, 堀 美香, 斯波 真理子, 水口 裕之

    日本薬学会年会要旨集   Vol. 140年会   page: 26G - pm16S   2020.3

     More details

    Language:Japanese   Publisher:(公社)日本薬学会  

  11. 家族性高コレステロール血症(Familial Hypercholesterolemia)の遺伝学的検査における大規模重複・欠損を検出目的としたMLPA法の導入

    山本 賢, 礒田 理恵子, 中西 啓美, 堀 美香, 孫 徹, 古田 賢二, 斯波 真理子, 宮本 恵宏

    国立病院総合医学会講演抄録集   Vol. 73回   page: P2 - 1689   2019.11

     More details

    Language:Japanese   Publisher:国立病院総合医学会  

  12. 遺伝性循環器疾患に対する遺伝子解析の実践 家族性高コレステロール血症の遺伝子解析とその有用性

    堀 美香, 斯波 真理子

    日本心臓病学会学術集会抄録   Vol. 67回   page: S7 - 3   2019.9

     More details

    Language:Japanese   Publisher:(一社)日本心臓病学会  

  13. LDLRとPCSK9遺伝子変異に関する二重ヘテロ接合体における実在する心血管リスク(Substantial Cardiovascular Risks in Double-heterozygotes for LDLR and PCSK9 Gene Variants)

    土井 貴仁, 堀 美香, 斯波 真理子, 片岡 有, 西村 邦宏, 西川 諒, 津田 浩佑, 小倉 正恒, 孫 徹, 宮本 恵宏, 野口 暉夫, 下川 宏明, 安田 聡

    日本心臓病学会学術集会抄録   Vol. 67回   page: YIA - 2   2019.9

     More details

    Language:English   Publisher:(一社)日本心臓病学会  

  14. 心肺停止を伴う急性心筋梗塞を契機に診断に至った1型CD36欠損症および家族性高コレステロール血症の合併例

    西川 諒, 古橋 眞人, 伊藤 良介, 續 太郎, 小山 雅之, 村中 敦子, 國分 宣明, 堀 美香, 小倉 正恒, 斯波 真理子, 三浦 哲嗣

    日本動脈硬化学会総会プログラム・抄録集   Vol. 51回   page: 1 - 3   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  15. 家族性高コレステロール血症(Familial Hypercholesterolemia)の遺伝学的検査におけるMLPA法導入の報告

    礒田 理恵子, 山本 賢, 増田 弘明, 堀 美香, 孫 徹, 古田 賢二, 斯波 真理子, 宮本 恵宏

    日本動脈硬化学会総会プログラム・抄録集   Vol. 51回   page: 1 - 4   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  16. 家族性高コレステロール血症患者における遺伝子変異によるアキレス腱肥厚への影響

    道倉 雅仁, 堀 美香, 小倉 正恒, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 51回   page: 2 - 2   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  17. 心肺停止を伴う急性心筋梗塞を契機に診断に至った1型CD36欠損症および家族性高コレステロール血症の合併例

    西川 諒, 古橋 眞人, 伊藤 良介, 續 太郎, 小山 雅之, 村中 敦子, 國分 宣明, 堀 美香, 小倉 正恒, 斯波 真理子, 三浦 哲嗣

    日本動脈硬化学会総会プログラム・抄録集   Vol. 51回   page: 1 - 3   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  18. プラスミド特異的ヒストンアセチル化酵素リクルートシステムの効果はin vivoでは観察されない

    紙谷 浩之, 鈴木 哲矢, 若尾 祐介, 渡部 匡史, 堀 美香, 池田 義人, 土谷 博之, 小暮 健太朗, 斯波 真理子, 藤室 雅弘

    日本DDS学会学術集会プログラム予稿集   Vol. 35回   page: 182 - 182   2019.6

     More details

    Language:Japanese   Publisher:日本DDS学会  

  19. Prevalence, Clinical Characteristics and Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia Patients With Double-Heterozygous Mutation of LDLR and PCSK9 Gain-Of-Function Mutation

    Takahito Doi, Mika Hori, Mariko Harada-Shiba, Yu Kataoka, Ryo Nishikawa, Kosuke Tsuda, Kunihiro Nishimura, Masatsune Ogura, Teruo Noguchi, Satoshi Yasuda

    CIRCULATION   Vol. 138   2018.11

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    0

    Web of Science

  20. FHホモ接合体におけるコレステロール引き抜き能

    小倉 正恒, 堀 美香, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 50回   page: 285 - 285   2018.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  21. 家族性高コレステロール血症ヘテロ接合体における遺伝子診断とLDLR/PCSK9遺伝子変異の分布

    堀 美香, 太田 直孝, 増田 弘明, 磯田 理恵子, 孫 徹, 小倉 正恒, 細田 公則, 宮本 恵宏, 斯波 真理子

    日本臨床分子医学会学術総会プログラム・抄録集   Vol. 55回   page: 65 - 65   2018.4

     More details

    Language:Japanese   Publisher:日本臨床分子医学会  

  22. Clinical and Cardiovascular Outcomes in Double Heterozygous Familial Hypercholesterolemia with LDLR and PCSK9 Mutations: Insights from Genetically-diagnosed HeFH Database(和訳中)

    土井 貴仁, 堀 美香, 片岡 有, 浅海 泰栄, 西川 諒, 津田 浩佑, 小倉 正恒, 野口 暉夫, 斯波 真理子, 安田 聡

    日本循環器学会学術集会抄録集   Vol. 82回   page: OJ11 - 1   2018.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

  23. LDLRおよびPCSK9変異を有する二重ヘテロ接合性家族性高コレステロール血症における臨床および心血管転帰 遺伝子診断によるHeFHデータベースからの知見(Clinical and Cardiovascular Outcomes in Double Heterozygous Familial Hypercholesterolemia with LDLR and PCSK9 Mutations: Insights from Genetically-diagnosed HeFH Database)

    土井 貴仁, 堀 美香, 片岡 有, 浅海 泰栄, 西川 諒, 津田 浩佑, 小倉 正恒, 野口 暉夫, 斯波 真理子, 安田 聡

    日本循環器学会学術集会抄録集   Vol. 82回   page: OJ11 - 1   2018.3

     More details

    Language:English   Publisher:(一社)日本循環器学会  

  24. 脂質代謝異常症への多角的アプローチ PCSK9 家族性高コレステロール血症の病態および治療への関与

    太田 直孝, 堀 美香, 宮本 恵宏, 斯波 真理子

    The Lipid   Vol. 29 ( 1 ) page: 106 - 112   2018.1

     More details

    Language:Japanese   Publisher:(株)メディカルレビュー社  

  25. 抗動脈硬化作用を有する間葉系幹細胞培養上清の血管内皮細胞,マクロファージに対する作用機序の解析

    高藤義正, 堀美香, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 49th   page: 290 (WEB ONLY) - 290   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  26. GLP‐1受容体作動薬のLDL‐コレステロール低下作用とその機序に関する検討

    長谷川夕希子, 堀美香, 中神朋子, 内潟安子, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 49th   page: 225 (WEB ONLY) - 225   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  27. GLP-1受容体作動薬のLDL-コレステロール低下作用とその機序に関する検討

    長谷川 夕希子, 堀 美香, 中神 朋子, 内潟 安子, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 49回   page: 225 - 225   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  28. Glucagon-Like Peptide-1 Receptor Agonists Reduce Serum LDL Cholesterol Levels via LDL Receptor in Mice and Type 2 Diabetes Patient

    Yukiko Hasegawa, Mika Hori, Tomoko Nakagami, Mariko Harada-Shiba, Yasuko Uchigata

    DIABETES   Vol. 66   page: A166 - A166   2017.6

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER DIABETES ASSOC  

    Web of Science

  29. 抗動脈硬化作用を有する間葉系幹細胞培養上清の血管内皮細胞、マクロファージに対する作用機序の解析

    高藤 義正, 堀 美香, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 49回   page: 290 - 290   2017.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  30. GLP-1受容体作動薬の脂質代謝に及ぼす影響とその機序に関する検討

    長谷川 夕希子, 堀 美香, 中神 朋子, 斯波 真理子, 内潟 安子

    糖尿病   Vol. 60 ( Suppl.1 ) page: S - 462   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

  31. GLP-1受容体作動薬の脂質代謝に及ぼす影響とその機序に関する検討

    長谷川 夕希子, 堀 美香, 中神 朋子, 斯波 真理子, 内潟 安子

    糖尿病   Vol. 60 ( Suppl.1 ) page: S - 462   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

  32. 脂肪由来間葉系幹細胞培養上清の抗動脈硬化作用における機序の解析

    高藤義正, 堀美香, 斯波真理子

    再生医療   Vol. 16   page: 369   2017.2

     More details

    Language:Japanese  

    J-GLOBAL

  33. 家族性高コレステロール血症診断・治療の新たな展開―PCSK9を中心として―

    堀美香, 斯波真理子

    循環器病研究の進歩   Vol. 37 ( 1 ) page: 81‐87 - 87   2016.11

     More details

    Language:Japanese   Publisher:(株)協和企画  

    J-GLOBAL

  34. LDLアフェレシスにより除去されるタンパク質の解析 FHと末梢動脈疾患

    堀 美香, 南野 直人, 斯波 真理子

    日本アフェレシス学会雑誌   Vol. 35 ( Suppl. ) page: 77 - 77   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本アフェレシス学会  

  35. CTを用いた病理組織像に相当する脂肪膵画像の評価

    堀 美香, 女屋 博昭, 平岡 伸介, 山地 太樹, 高橋 真美, 武藤 倫弘, 中釜 斉

    日本癌学会総会記事   Vol. 75回   page: P - 1321   2016.10

     More details

    Language:English   Publisher:日本癌学会  

  36. 家族性高コレステロール血症の残余リスクとしてのHDL機能

    小倉正恒, 森本めぐむ, 太田愛美, 道倉雅仁, 堀美香, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 48th   page: 122 (WEB ONLY)   2016.6

     More details

    Language:Japanese  

    J-GLOBAL

  37. 家族性高コレステロール血症ホモ接合体Up to date

    小倉正恒, 堀美香, 槇野久士, 玉那覇民子, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 48th   page: 113 (WEB ONLY)   2016.6

     More details

    Language:Japanese  

    J-GLOBAL

  38. PCSK9 V4I変異とE32K変異を有する家系について

    太田直孝, 太田直孝, 堀美香, 増田弘明, 増田弘明, 藤山啓美, 藤山啓美, 新井浩司, 宮本恵宏, 宮本恵宏, 斯波真理子, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 48回   page: 222 - 222   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  39. 間葉系幹細胞培養上清の血中投与によるLDL受容体欠損マウスにおける抗動脈硬化作用

    高橋 義正, 堀 美香, 水野 敏秀, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 48回   page: 255 - 255   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  40. HDLの機能評価とHDLを標的とした薬剤開発の将来展望 家族性高コレステロール血症の残余リスクとしてのHDL機能

    小倉 正恒, 森本 めぐむ, 太田 愛美, 道倉 雅仁, 堀 美香, 斯波 真理子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 48回   page: 122 - 122   2016.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  41. 脂肪由来間葉系幹細胞培養上清のLDL受容体欠損マウスへの血中投与による動脈硬化抑制効果

    高藤義正, 堀美香, 斯波真理子

    再生医療   Vol. 15   page: 248   2016.2

     More details

    Language:Japanese  

    J-GLOBAL

  42. ApoE/NMU二重欠損マウスにおける脂質代謝及び動脈硬化初期病変の評価

    堀 美香, 水野 敏秀, 斯波 真理子

    日本生化学会大会・日本分子生物学会年会合同大会講演要旨集   Vol. 88回・38回   page: [2P1245] - [2P1245]   2015.12

     More details

    Language:English   Publisher:(公社)日本生化学会  

  43. 家族性高コレステロール血症の残存リスクとしてのLDL粒子の質的評価

    小倉正恒, 道倉雅仁, 冨家千鶴, 堀美香, 森本めぐむ, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 47th   page: 171 (WEB ONLY) - 171   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  44. 間葉系幹細胞培養上清(MSC‐CM)の動脈硬化性病変を形成する細胞に対する抗炎症作用

    高藤義正, 堀美香, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 47th   page: 238 (WEB ONLY) - 238   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  45. 新規分子非ヘテロダイマー型60kDa PCSK9特異的ELISAの構築と血中動態

    岩崎忠雄, 石原光昭, 鯨岡健, 小川一行, 服部浩明, 堀美香, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 47th   page: 224 (WEB ONLY) - 224   2015.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  46. 動脈硬化性病変を形成する細胞に対する脂肪由来間葉系幹細胞培養上清の抗炎症作用

    高藤義正, 堀美香, 斯波真理子

    再生医療   Vol. 14   page: 361   2015.2

     More details

    Language:Japanese  

    J-GLOBAL

  47. LDLアフェレーシス療法施行中の重症家族性高コレステロール血症に対する,同種脂肪組織由来多系統前駆細胞(ADMPC)を用いた細胞移植療法の確立 実施体制の確立と調整(患者会での広報)

    斯波真理子, 小倉正恒, 堀美香

    LDLアフェレーシス療法施行中の重症家族性高コレステロール血症に対する、同種脂肪組織由来多系統前駆細胞(ADMPC)を用いた細胞移植療法の確立 平成26年度 委託業務成果報告書     page: 154 - 167   2015

     More details

    Language:Japanese  

    J-GLOBAL

  48. ヒト血中におけるPCSK9の分子形態の解析

    鯨岡健, 石原光昭, 岩崎忠雄, 小川一行, 服部浩明, 堀美香, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 46th   page: 1-P-104 (WEB ONLY) - 247   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  49. Proprotein convertase subtilisin/kexin type9(PCSK9)非ヘテロダイマー型mature segment分子のLDL受容体分解活性

    石原光昭, 鯨岡健, 岩崎忠雄, 小川一行, 服部浩明, 堀美香, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 46th   page: 1-P-105 (WEB ONLY) - 248   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  50. 超音波で測定したアキレス腱厚と頸動脈内膜中膜複合体厚の関連

    道倉雅仁, 小倉正恒, 冨家千鶴, 肥後諒, 菱田藍, 橡谷真由, 大畑洋子, 玉那覇民子, 槇野久士, 柴田映子, 堀美香, 岸本一郎, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 46th   page: 1-P-58 (WEB ONLY) - 225   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  51. GLP‐1のコレステロール代謝に及ぼす影響

    長谷川夕希子, 堀美香, 中神朋子, 斯波真理子, 内潟安子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 46th   page: 1-P-62 (WEB ONLY)   2014.6

     More details

    Language:Japanese  

    J-GLOBAL

  52. GLP-1のクレステロール代謝に及ぼす影響

    長谷川 夕希子, 堀 美香, 中神 朋子, 斯波 真理子, 内潟 安子

    日本動脈硬化学会総会プログラム・抄録集   Vol. 46回   page: 227 - 227   2014.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

  53. Gadofluorine Mによるマウスの動脈硬化プラークイメージング

    圓見純一郎, 柴田映子, 柴田雅朗, 森本めぐむ, 福田肇, 橋川美子, 河嶋秀和, 堀美香, 斯波真理子, 飯田秀博

    JSMI Rep   Vol. 7 ( 2 ) page: 155 - 155   2014.5

     More details

    Language:Japanese   Publisher:日本分子イメージング学会  

    J-GLOBAL

  54. 肝細胞におけるGLP‐1のコレステロール代謝に及ぼす影響

    長谷川夕希子, 堀美香, 中神朋子, 斯波真理子, 内潟安子

    糖尿病   Vol. 57 ( Supplement 1 ) page: S.418 - 418   2014.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    J-GLOBAL

  55. LDLアフェレシスの新たな作用機序と臨床応用 家族性高コレステロール血症に対するLDL-Aの効果

    斯波 真理子, 槇野 久士, 堀 美香, 玉那覇 民子, 小倉 正恒, 肥塚 諒, 菱田 藍, 長谷川 夕希子, 岸本 一郎, 南野 直人

    医工学治療   Vol. 26 ( Suppl. ) page: 78 - 78   2014.3

     More details

    Language:Japanese   Publisher:(NPO)日本医工学治療学会  

  56. 家族性高コレステロール血症に対するLDL‐Aの効果

    斯波真理子, 槇野久士, 堀美香, 玉那覇民子, 小倉正恒, 肥塚諒, 菱田藍, 長谷川夕希子, 岸本一郎, 南野直人

    医工学治療   Vol. 26 ( Supplement ) page: 78   2014

     More details

    Language:Japanese  

    J-GLOBAL

  57. ニューロメジンUの脂質代謝及び動脈硬化との関わり

    堀美香, 水野敏秀, 斯波真理子

    日本内分泌学会雑誌   Vol. 89 ( 2 ) page: 740 - 740   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    J-GLOBAL

  58. 家族性高コレステロール血症患者における超音波によるアキレス腱計測の評価

    道倉雅仁, 冨家千鶴, 槇野久士, 橡谷真由, 玉那覇民子, 大畑洋子, 吉田晶子, 森本めぐむ, 柴田映子, 堀美香, 岸本一郎, 斯波真理子

    日本動脈硬化学会総会・学術集会プログラム・抄録集(Web)   Vol. 45th   page: 1-P-63 (WEB ONLY) - 226   2013.6

     More details

    Language:Japanese   Publisher:(一社)日本動脈硬化学会  

    J-GLOBAL

  59. コレステロール代謝におけるニューロメジンUの役割と動脈硬化との関連

    堀美香, 駒井仁美, 水野敏秀, 斯波真理子

    日本分子生物学会年会プログラム・要旨集(Web)   Vol. 36th   page: 3P-0885 (WEB ONLY)   2013

     More details

    Language:Japanese  

    J-GLOBAL

  60. 脂肪膵の膵がんにおける意義及びCTを用いた評価方法の確立(The role of fatty infiltration on pancreatic cancer and establishment of the evaluation method using CT imaging)

    堀 美香, 高橋 真美, 女屋 博昭, 平岡 伸介, 山地 太樹, 武藤 倫弘, 金井 弥栄, 中釜 斉

    日本癌学会総会記事   Vol. 71回   page: 356 - 356   2012.8

     More details

    Language:English   Publisher:日本癌学会  

  61. 生理活性ペプチドニューロメジンUの脂質代謝及び炎症における役割

    堀美香, 斯波真理子

    日本分子生物学会年会プログラム・要旨集(Web)   Vol. 35th   page: 4P-0548 (WEB ONLY)   2012

     More details

    Language:Japanese  

    J-GLOBAL

  62. ヒト膵がん発生における脂肪膵の意義(The role of fatty infiltration in the pancreas on the development of pancreatic cancer in humans)

    堀 美香, 平岡 伸介, 高橋 真美, 武藤 倫弘, 山地 太樹, 金井 弥栄, 中釜 斉

    日本癌学会総会記事   Vol. 70回   page: 67 - 67   2011.9

     More details

    Language:English   Publisher:日本癌学会  

  63. アディポネクチンが欠損したMin及びC57BLマウスにおける腸発がん促進(Enhancement of intestinal carcinogenesis in Min and C57BL mice with adiponectin deficiency)

    武藤 倫弘, 高橋 真美, 山本 真史, 堀 美香, 若林 敬二, 中釜 斉

    日本癌学会総会記事   Vol. 70回   page: 290 - 290   2011.9

     More details

    Language:English   Publisher:日本癌学会  

  64. 膵臓特異的K-ras変異体発現マウスの膵臓発がんにおけるオステオポンチンの発現上昇(Increased expression of osteopontin in pancreatic carcinogenesis in pancreas-specific K-ras mutant mice)

    高橋 真美, 石ヶ守 里加子, 堀 美香, 高須 伸二, 今井 俊夫, 武藤 倫弘, 若林 敬二

    日本癌学会総会記事   Vol. 70回   page: 159 - 159   2011.9

     More details

    Language:English   Publisher:日本癌学会  

  65. 膵がん発生における脂肪膵の意義に関する研究

    堀美香, 平岡伸介, 高橋真美, 武藤倫弘, 金井弥栄, 中釜斉

    がん予防大会プログラム・抄録集   Vol. 2011   page: 71   2011

     More details

    Language:Japanese  

    J-GLOBAL

  66. アゾキシメタン誘発大腸aberrant crypt fociの生成に対する肥満・糖尿病の影響の検討

    伊藤久美子, 高橋真美, 堀美香, 石ケ守里加子, 武藤倫弘, 中釜斉, 太田敏博

    がん予防大会プログラム・抄録集   Vol. 2011   page: 68   2011

     More details

    Language:Japanese  

    J-GLOBAL

  67. Adiponectin遺伝子欠損によるマウスの腸発がん促進作用

    武藤倫弘, 寺岡直哉, 小沼邦重, 高橋真美, 堀美香, 中野勝也, 一二三佳恵, 窪田直人, 門脇孝, 若林敬二, 中釜斉

    がん予防大会プログラム・抄録集   Vol. 2011   page: 48   2011

     More details

    Language:Japanese  

    J-GLOBAL

  68. Low density lipoprotein受容体欠損の大腸aberrant crypt foci生成に対する影響

    中野勝也, 武藤倫弘, 小沼邦重, 高橋真美, 堀美香, 一二三佳恵, 谷中昭典, 若林敬二, 中釜斉

    がん予防大会プログラム・抄録集   Vol. 2011   page: 67   2011

     More details

    Language:Japanese  

    J-GLOBAL

  69. 8‐Hydroxy‐dGTP(8‐oxo‐7,8‐dihydro‐dGTP)二次酸化産物の変異誘発能

    紙谷浩之, 堀美香, 原島秀吉

    日本放射線影響学会大会講演要旨集   Vol. 53rd   page: 91 - 91   2010.10

     More details

    Language:Japanese   Publisher:(一社)日本放射線影響学会  

    DOI: 10.11513/jrrsabst.2010.0.113.0

    J-GLOBAL

  70. ハムスター膵管発がんにおけるオステオポンチンとそのスプライシングバリアントの発現上昇(Increased expression of osteopontin and its splicing variants in hamster pancreatic ductal carcinogenesis)

    高橋 真美, 石ヶ守 里加子, 堀 美香, 小宮 雅美, 武藤 倫弘, 杉村 隆, 若林 敬二

    日本癌学会総会記事   Vol. 69回   page: 89 - 89   2010.8

     More details

    Language:English   Publisher:日本癌学会  

  71. 肥満KK-AyマウスにおけるアンギオテンシンII受容体拮抗薬の大腸発がんに与える影響(Effects of an angiotensin II receptor blocker on colon carcinogenesis in obese KK-Ay mouse)

    高須 伸二, 武藤 倫弘, 寺岡 直哉, 上野 俊也, 小沼 邦重, 高橋 真美, 堀 美香, 杉村 隆, 若林 敬二

    日本癌学会総会記事   Vol. 69回   page: 259 - 259   2010.8

     More details

    Language:English   Publisher:日本癌学会  

  72. 高脂肪食によるBOP誘発ハムスター膵管発がん促進因子の検討(Promotion factors of pancreatic carcinogenesis in BOP-treated hamsters fed a high fat diet)

    堀 美香, 北橋 宗, 高橋 真美, 今井 俊夫, 石ヶ守 里加子, 高須 伸二, 武藤 倫弘, 杉村 隆, 若林 敬二

    日本癌学会総会記事   Vol. 69回   page: 89 - 89   2010.8

     More details

    Language:English   Publisher:日本癌学会  

  73. ヒトNUDT5蛋白質は様々な酸化デオキシリボヌクレオシドニリン酸を分解する

    紙谷浩之, 堀美香, 有森貴夫, 関口睦夫, 山縣ゆり子, 原島秀吉

    生化学     page: ROMBUNNO.3T18P-15   2009.9

     More details

    Language:Japanese  

    J-GLOBAL

  74. ヒトNUDT5蛋白質は様々な酸化デオキシリボヌクレオシド二リン酸を分解する

    紙谷 浩之, 堀 美香, 有森 貴夫, 関口 睦夫, 山縣 ゆり子, 原島 秀吉

    日本生化学会大会プログラム・講演要旨集   Vol. 82回   page: 3T18p - 15   2009.9

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

  75. マウスでのアディポネクチンの腸発がんにおける役割(Role of adiponectin in intestinal carcinogenesis in mice)

    武藤 倫弘, 飯郷 正明, 寺岡 直哉, 上野 俊也, 高橋 真美, 高須 伸二, 堀 美香, 杉村 隆, 若林 敬二

    日本癌学会総会記事   Vol. 68回   page: 74 - 74   2009.8

     More details

    Language:English   Publisher:日本癌学会  

  76. ヌクレオチドプール浄化酵素は、ヒト細胞において8-ヒドロキシ-dGTPにより誘発される変異を抑制する(Nucleotide pool sanitization enzymes suppress the mutation induced by 8-hydroxy-dGTP in human cells)

    堀 美香, 原島 秀吉, 紙谷 浩之

    日本癌学会総会記事   Vol. 68回   page: 39 - 39   2009.8

     More details

    Language:English   Publisher:日本癌学会  

  77. NUDT5は幅広い基質特異性を有する酸化dNDP分解酵素である(NUDT5 hydrolyzes oxidized deoxyribo nucleoside diphosphates with broad substrate specificity)

    紙谷 浩之, 堀 美香, 関口 睦夫, 原島 秀吉

    日本癌学会総会記事   Vol. 68回   page: 377 - 377   2009.8

     More details

    Language:English   Publisher:日本癌学会  

  78. P-006 8-Hydroxyguanine and translesion synthesis DNA polymerases(Poster Session)

    Kamiya Hiroyuki, Yamaguchi Ayaka, Suzuki Tetsuya, Satou Kazuya, Hori Mika, Kawai Kazuaki, Kasai Hiroshi, Harashima Hideyoshi

    Taikai Program Yoshisyu of the Environmental Mutagen Society of Japan   ( 37 )   2008.11

     More details

    Language:Japanese   Publisher:日本環境変異原学会  

  79. 8‐ヒドロキシグアニンが誘発する変異と損傷乗り越えDNAポリメラーゼ

    紙谷浩之, 山口彩花, 鈴木哲矢, 佐藤和哉, 堀美香, 河井一明, 葛西宏, 原島秀吉

    日本環境変異原学会大会プログラム・要旨集   Vol. 37th   page: 109   2008.11

     More details

    Language:Japanese  

    J-GLOBAL

  80. 哺乳動物細胞におけるヌクレオチドプール浄化酵素の8‐hydroxy‐dGTP誘発変異の抑制

    堀美香, 原島秀吉, 紙谷浩之

    日本放射線影響学会大会講演要旨集   Vol. 51st   page: 87 - 87   2008.11

     More details

    Language:Japanese   Publisher:(一社)日本放射線影響学会  

    DOI: 10.11513/jrrsabst.2008.0.108.0

    J-GLOBAL

  81. 哺乳動物細胞におけるヌクレオチドプール浄化酵素の酸化損傷ヌクレオチド誘発変異に対する影響

    堀美香, 原島秀吉, 紙谷浩之

    生化学   Vol. 81回・31回   page: 4T4-8 - 8   2008.11

     More details

    Language:Japanese   Publisher:(公社)日本生化学会  

    J-GLOBAL

  82. UvrAとUvrBは酸化損傷ヌクレオチドにより誘発される変異を促進する

    堀美香, 石黒智恵子, 鈴木哲矢, 中川紀子, 布柴達男, 倉光成紀, 山本和生, 葛西宏, 原島秀吉, 紙谷浩之

    日本放射線影響学会大会講演要旨集   Vol. 50th   page: 69 - 69   2007.11

     More details

    Language:Japanese   Publisher:(一社)日本放射線影響学会  

    J-GLOBAL

  83. 損傷ヌクレオチドによる遺伝情報不安定性誘発とその制御 酸化ヌクレオチド誘発変異とヌクレオチド除去修復酵素UvrABCとの関連

    堀 美香, 石黒 智恵子, 中川 紀子, 倉光 成紀, 山本 和生, 葛西 宏, 原島 秀吉, 紙谷 浩之

    日本放射線影響学会大会講演要旨集   Vol. 49回   page: 75 - 75   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本放射線影響学会  

  84. 酸化ヌクレオチド誘発変異とヌクレオチド除去修復酵素UvrABCとの関連

    堀美香, 石黒智恵子, 中川紀子, 倉光成紀, 山本和生, 葛西宏, 原島秀吉, 紙谷浩之

    日本放射線影響学会大会講演要旨集   Vol. 49th   page: 75   2006

     More details

    Language:Japanese  

    J-GLOBAL

  85. ヌクレオチドプール浄化酵素Orf17のアンチセンス遺伝子導入の効果

    堀美香, 原島秀吉, 紙谷浩之

    日本分子生物学会年会講演要旨集   Vol. 28th   page: 197   2005.11

     More details

    Language:Japanese  

    J-GLOBAL

  86. γ線照射,活性窒素により生じる損傷ヌクレオチドのin vivoにおける変異誘発能の解析

    堀美香, 石黒智恵子, 原島秀吉, 紙谷浩之

    日本分子生物学会年会プログラム・講演要旨集   Vol. 27th   page: 634   2004.11

     More details

    Language:Japanese  

    J-GLOBAL

  87. 大腸菌Orf17蛋白質の酸化損傷ヌクレオチド分解活性

    堀美香, 藤川勝義, 葛西宏, 原島秀吉, 紙谷浩之

    日本分子生物学会年会プログラム・講演要旨集   Vol. 26th   page: 946   2003.11

     More details

    Language:Japanese  

    J-GLOBAL

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 7

  1. Homeostatic regulation of amino acid metabolism through the viewpoint of glucagon and liver zonation.

    Grant number:22H03508  2022.4 - 2027.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Authorship:Coinvestigator(s) 

  2. 膵内分泌腫瘍モデルマウスを用いたアミノ酸代謝異常を介した発がん機構の解明

    Grant number:21K08705  2021.4 - 2024.3

    堀 美香

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

  3. アキレス腱の軟らかさに着目した家族性高コレステロール血症・新診断法の確立

    Grant number:19H00455  2019

    日本学術振興会  科学研究費助成事業 奨励研究  奨励研究

    道倉 雅仁, 斯波 真理子, 小倉 正恒, 堀 美香, 松木 恒太, 山本 真大

      More details

    家族性高コレステロール血症(FH)はLDL-コレステロール(LDL-C)が高値を示す遺伝的疾患である。本国でのFH診断率は0.1%程度と報告されており、FH診断率の向上は重要未解決問題である。現在の診断基準の1つであるアキレス腱の厚さに加え軟らかさも評価することによりFH検出能が向上するか研究したところ、検出能が80%から86%と向上し、アキレス腱厚が正常で従来見逃されていた患者、特に若年者や女性を診断することができた。

  4. Elucidation of the effect of variants in the PCSK9 gene and molecular type on lifestyle-related diseases and its regulatory mechanism

    Grant number:17K08681  2017.4 - 2020.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Hori Mika

      More details

    Authorship:Principal investigator 

    Grant amount:\4810000 ( Direct Cost: \3700000 、 Indirect Cost:\1110000 )

    The variants in the PCSK9 gene detected in Japan were annotated in familial hypercholesterolemia (FH) according to ACMG guideline. The E32K variant in the PCSK9 gene can cause FH, but the V4I variant alone does not contribute to the pathophysiology of FH. The V4I・E32K variants in the PCSK9 gene showed no difference in the levels of intracellular expression and secretion of PCSK9, intracellular and membrane expression of LDLR and LDL uptake compared to wild type of PCSK9 using cultured cells. In addition, the prevalence of diabetes mellitus was lower in patients with variants in the LDLR and PCSK9 genes than in patients without variants in the LDLR and PCSK9 genes. Patients with FH with variants in the LDLR gene and V4I/E32K variant in the PCSK9 gene had poor prognosis compared to patients with a variant in the LDLR or PCSK9 gene.

  5. Involvement of the type of PCSK9 in familial hypercholesterolemia, obesity and diabetes

    Grant number:15K19038  2015.4 - 2017.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    Mika Hori

      More details

    Authorship:Principal investigator 

    Grant amount:\3900000 ( Direct Cost: \3000000 、 Indirect Cost:\900000 )

    In familial hypercholesterolemia, there were no significant differences in serum lipid levels and the prevalence of coronary artery diseases (CADs) between PCSK9 V4I carriers and non-carriers without LDLR mutations. In the patients carrying LDLR mutations and aged 30 years or more, the additional PCSK9 V4I variant is linked to a significantly increased prevalence of CADs in accord with the elevation of the LDL-C level. In vitro experiments, there were no differences in the expression of LDLR and the uptake of LDL between PCSK9 V4I-expressed cells and PCSK9 WT-expressed cells. However, in a setting, the uptake of LDL was significantly decreased in PCSK9 V4I-expressed cells as compared with PCSK9 WT- expressed cells.
    In addition, there was inverse correlation between ratio of furin-cleaved PCSK9 to total PCSK9 and serum APOB level in patients with hypercholesterolemia. Thus, it is suggested that the rate of mature PCSK9 to total PCSK9 is associated with high LDL-C levels.

  6. The effect of neuromedin U to atherosclerosis caused by chronic inflammation

    Grant number:24790793  2012.4 - 2015.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)  Grant-in-Aid for Young Scientists (B)

    HORI Mika

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    Serum total cholesterol level was 2-fold higher in Apoe-/-Nmu-/- mice in Apoe-/- mice by a high-fat diet (HFD) treatment. However, there were no differences between both mice in atherosclerosis progression by both en face and aortic valve section analysis. There were no differences between peritoneal macrophages in both mice in the uptake of ox-LDL or the inflammation induced by ox-LDL treatment.
    Nmu-/- mice developed hepatic steatosis induced by HFD, but Apoe-/-Nmu-/- mice did not develop it but increased the number of lipid-laden macrophages. Our findings suggest that NMU has no effect on the development of atherosclerosis, but has significant roles in cholesterol metabolism and some inflammation reaction.

  7. dGTPの酸化損傷体の生細胞における変異誘発とその防御機構の解明

    Grant number:07J03120  2007 - 2008

    日本学術振興会  科学研究費助成事業 特別研究員奨励費  特別研究員奨励費

    堀 美香

      More details

    本研究では、酸化ストレスマーカーである8-hydroxyguanineのヌクレオチド体、8-hydroxy-dGTP(8-OH-dGTP)とその二次酸化体、spiroiminodihydantoin-2'-deoxynucleoside 5'-triphosphate(dSpTP)及びguanidinohydantoin-2'-deoxynucleoside 5'-triphosphate(dGhTP)の生細胞における変異誘発能とその除去にDNA修復機相が関与するか否かを明らかにすることを目的とする。
    1.dSpTP及びdGhTPの大腸菌における変異原性の評価とdSpTPやdGhTPを分解するヌクレオチドプール浄化酵素の探索:dSpTP及びdGhTPを大腸菌に直接導入し、変異体率を算出した。その結果、コントロールと比較して変異体率の上昇は観察されなかった。また、ヌクレオチドプール浄化酵素MTH1、MutT、Orf17蛋白質を精製し、dSpTPやdGhTPの分解活性を評価したが、分解活性は観察されなかった。
    2.哺乳動物細胞を用いたヌクレオチドプール浄化酵素の酸化損傷ヌクレオチド除去への関与:哺乳動物細胞のヌクレオチドプール浄化酵素MTH1、MTH2、NUDT5が8-OH-dGTPにより誘発される変異を抑制するか否か検討した。siRNAを用いて各蛋白質をノックダウンしたヒト293T細胞に8-OH-dGTPを直接導入し、誘発変異を調べた。その結果、MTH2及びNUDT5をノックダウンした細胞において、コントロールsiRNA導入時と比較し、8-OH-dGTP誘発変異が上昇し、さらに3種の蛋白質を同時にノックダウンすると、誘発変異が2倍に上昇した。このことから、MTH1、MTH2、NUDT5は、哺乳動物細胞において、互いに補完しあい、8-OH-dGTPにより誘発される変異を抑制していることが示唆された。

▼display all

Industrial property rights 1

  1. PCSK9関連薬剤のスクリーニング、又は、当該薬剤の投与効果の確認を行うためのPCSK9の測定方法

    石原 光昭, 鯨岡 健, 岩▲崎▼ 忠雄, 小川 一行, 服部 浩明, 星野 文則, 斯波 真理子, 堀 美香

     More details

    Applicant:株式会社ビー・エム・エル, 独立行政法人国立循環器病研究センター

    Application no:特願2014-111680  Date applied:2014.5

    Announcement no:特開2015-007622  Date announced:2015.1

    J-GLOBAL